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CHAPTER 1 
MOTIVATION AND BACKGROUND 
8 
Since the 1960s, several screening programmes for breast cancer detection 
have been carried out in North America and Western Europe. For women 
aged 50-69 years, the results in general consistently show benefits of mammo-
graphie screening, in particular a better stage distribution at diagnosis and a 
subsequent reduction in breast cancer mortality. In women younger than 50 
years, however, the benefits of screening are not clear. The interpretation of 
the results of randomised trials regarding the under age 50 group has been the 
subject of much controversy.1·2 
So far, the only evidence of the efficacy of screening the younger age group 
in reducing breast cancer mortality has come from the 18-year follow-up study 
of the Health Insurance Plan (HIP).3 Launched in 1963 in Greater New York, 
this was the first breast cancer screening randomised trial. Later on, in the 
1970s and 1980s, randomised trials were set up in Sweden (in the two counties 
of Kopparberg and Östergötland, as well as in Malmö, Stockholm and Gothen-
burg), in the United Kingdom (Edinburgh) and in Canada (the National Breast 
Screening Study, NBSS for short). These trials varied in terms of the screen-
ing test used (mammography or mammography and clinical breast examina-
tion) and frequency of screening. 
To assess the current state of knowledge, international conferences in the 
early '90s reviewed the effect of screening under age 50 and several over-
views were published.48 However, no unequivocal conclusions about the 
benefit of screening women aged 40 to 49 could be drawn. The duration of the 
follow-up period emerged as an especially important issue in assessing the 
efficacy of screening in the 40-49 age group. Figure 1.1 summarises the 
effects on breast cancer mortality of screening women under age 50 at entry of 
the project, according to the duration of the follow-up period.4·5 The HIP 
study is the only study to provide any information on long-term effects beyond 
12 years. It showed a benefit after 10 to 18 years of follow-up with a 25% 
mortality decrease. Pooling of the Swedish trials showed a non-significant 
13% decrease in mortality for study group women aged 40 to 49 after a fol-
low-up of 7 to 12 years. In summary, no benefit is evident at 5-7 years after 
entry, while at 10-12 years the benefit is uncertain and, if present, marginal. 
Some have argued that longer follow-up will be necessary to demonstrate 
any effectiveness of screening younger patients because these patients have a 
better relative survival. A large study on the long-term follow-up of breast 
cancer patients showed a 10-year relative survival rate of 64% for patients 
who were 40 to 49 at diagnosis, compared with 54% for those who were 50 to 
59.9 As younger patients live longer with breast cancer than older patients do, a 
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FIGURE 1.1 The risk ratio RR (on a logarithmic scale) of breast cancer 
death in women invited for screening versus non-invited women 
reported in randomised trials for women under age 50 at entry 
long delay is expected before any reduction in breast cancer mortality due to 
screening women under the age of 50 will become apparent. In summary, 
more information obtained through longer follow-up is needed before clear-cut 
conclusions can be drawn about any delayed effect of screening on mortality. 
This thesis is a study of the results of the Nijmegen screening programme, 
set up in 1975 and the longest ongoing project in the world to date. In the 
early years of the Nijmegen programme case-control studies covering a period 
of just eight years were carried out to assess the effect of mammographie 
screening on breast cancer mortality.1011 The comparisons made in these 'case-
control' designed studies may suffer from selection bias due to different under­
lying mortality rates in the participating and non-participating groups.12 There­
fore, to prevent this kind of bias, in the present study the effects on breast 
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cancer mortality observed after 16 years of biennial screening of younger 
women are assessed in a cohort study comparing invited women with a high 
participation rate with non-invited women. Specifically, the breast cancer 
mortality among younger women invited to participate in the Nijmegen pro-
gramme is compared with the experience of women living in Arnhem, a 
comparable neighbouring city without a screening programme. 
The absence so far of a clear effect on breast cancer mortality for younger 
women in the international screening projects may be explained not only by 
the follow-up period being too short but also by other factors, for instance a 
possibly lower sensitivity of the mammographie screening test in this age 
group and the higher growth rate and the pathobiology of the tumour in 
younger women. A shortcoming of the mammographie screening test may be 
its inability to detect small breast cancers in the denser breasts of younger 
women early enough, when they are still curable. A lower sensitivity will also 
increase the number of missed cancers, which will be expressed in a relatively 
large number of clinically diagnosed cancers in the interscreening interval 
following a negative examination, the so-called interval cancers. 
Furthermore, many experts believe that the lack of benefit can be attributed 
to the screening interval being too long. In their view, mammographie screen-
ing should be performed annually because of the assumed higher growth rate 
of tumours in younger patients. The availability of serial screening mammo-
grams in the Nijmegen project provides an opportunity to calculate the growth 
rates of breast cancers. 
An underlying premise for screening to be potentially effective is that breast 
cancer is a progressive disease and that advancing the time of diagnosis can 
improve the prognosis of patients. The value of early diagnosis depends on the 
time gained by early diagnosis through screening, the so-called lead time, and 
on the number of breast cancer cases that are still curable at that time. If in 
younger patients breast cancers metastasize in an early phase of development, 
a long lead time is required to detect most tumours in a curable stage. All 
these hypotheses will be studied within the framework of the Nijmegen screen-
ing programme. The issue of cost-effectiveness of a screening programme 
starting at age 40 (or 45) versus age 50 is beyond the scope of this study.13·14 
After a literature review of the effect of screening younger women in Chap-
ter 2, this thesis presents in Chapter 3 the results of the screening programme 
in Nijmegen regarding the observed versus expected breast cancer mortality. 
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The subsequent chapters deal with the determinants of the effects on breast 
cancer mortality. The growth rate of the tumour and the sensitivity of the 
mammographie screening test, which are factors related to the occurrence of 
interval cancers, are quantified age-specifically in Chapters 4 and 5, respec-
tively. Chapter 6 is an assessment of early indicators of screening effective-
ness, such as the proportion of screen-detected cancers among all cancers and 
the disease stage at diagnosis. Chapter 7 deals with the prognosis of early 
invasive breast cancers for the purpose of the discussion of the potential 
impact of screening. To resolve the issue of the efficacy of breast cancer 
screening in younger women, plans are being made to set up a new interna-
tional trial. Two approaches for the determination of the sample size, i.e. the 
number of women to be enrolled in the trial, are presented in Chapter 8, being 
of value in the discussion of the feasibility of such a 'giga' trial. Finally, in 
Chapter 9 the contribution of the Nijmegen results to the international dis-
cussion on the effectiveness of screening younger women is expounded. 
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CHAPTER 2 
MASS SCREENING FOR BREAST CANCER IN WOMEN YOUNGER 
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INTRODUCTION 
In the Netherlands, almost 50% of women diagnosed with breast cancer after 
giving rise to symptoms, die from the disease.1 In the near future, no further 
improvement in the prognosis and the therapeutic modalities is expected. 
Systematic early detection by screening appears to be the only way to decrease 
mortality from this disease. The best method to achieve this goal is mass 
screening with mammography. 
The debate about the age range for which screening is beneficial is still 
going on at an international level. The beneficial effect of periodic screening 
in women older than 50 years of age is generally recognized. For this age 
group the projects in the Netherlands as well as in other countries show a 
reduction in breast cancer mortality of 20-50% after a follow-up period of 5 to 
8 years. In women younger than 50 years, however, mammographie screening 
is controversial.2,3 
The aim of this paper is to review the factors that play a role in this debate 
and to address the effect of screening on mortality in this age group. 
MASS SCREENING PROJECTS 
To quantify the effect of screening on breast cancer mortality, several mass 
screening projects have been implemented. Some of these projects are 
designed as randomised trials. In Table 2.1 the results of the published studies 
are presented, by age at first invitation to participate in the screening pro-
gramme. 
The findings for women older than 50 years of age at first invitation are 
consistent: 7 years after the start of the screening project an average reduction 
of 30% in breast cancer mortality is observable. For women younger than 50 
years of age at first invitation the results are not as clear. Over the first 8 
years after the start of screening no reduction in breast cancer mortality is 
observed. In fact, three screening projects even show an increase in breast 
cancer mortality in younger women in the first few years of screening. In 
particular the American Health Insurance Plan (HIP) study confirms that no 
effect is yet to be expected in the first years of screening. 
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TABLE 2.1 The reduction in mortality from breast cancer by age at first invi­
tation to participate in the screening 
Study (Mean) Age group Reduction in 95 % Age group Reduction in 95 % 
follow-up at entry breast cancer confidence at entry breast cancer confidence 
period (years) mortality limits (years) mortality limits 
(years) (%) (%) 
Randomised trials 
HIP' 
(USA)4' 
Two-county 
(Sweden)6' 
Malmo 
(Sweden)8 
Edinburgh 
(Scotland)' 
5 
10 
18 
6 
79 
88 
7 
Case-control studies 
Nijmegen 
(the Netherlands)1 
Utrecht 
(the Netherlands)1 
Florence 
duly)13 
8 
0 II 
7 
2 
7 
40-49 
40-49 
45-54 
3549 
40-49 
5 
24 
25 
-26 
8 
-29 
-23 
32 
(screened at 
least twice) 
-78-49 
-16-50 
- 9 4 8 
-184-44 
-6048 
-125-26 
-381-69 
-53-69 
50-64 
50-74 
55-69 
50-64 
50-64 
50-64 
50-70 
53 
32 
21 
39 
34 
21 
20 
74 
70 
76 
(screened at 
least twice) 
21-73 
4-51 
-6-42 
16-56 
1648 
-24-49 
-1746 
33-90 
30-87 
57-87 
Observational study, comparison with national mortality statistics 
BCDDP' 9 3549 И 50-74 25 
(USA)14 
HIP = Health Insurance Plan. 
+
 BCDDP = Breast Cancer Detection Demonstration Project. 
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EPIDEMIOLOGIC AND BIOLOGIC BACKGROUNDS 
This section provides information about breast cancer in women younger and 
older than 50 years of age, respectively, in support of the argument about the 
anticipated effect of screening women in these age groups. 
Incidence by age 
In the Netherlands (see Table 2.2) as well as in other countries the relationship 
between the incidence of breast cancer and age shows that incidence increases 
proportionally faster in younger women than in older women.1617 The transi-
tion point ('Clemmesen's hook') lies around the age at menopause. However, 
this is not to say that the faster increase in incidence under the age of 50 is 
associated with a higher growth rate of the carcinomas in younger women and 
that, consequently, screening is bound to have less effect in this age group. 
TABLE 2.2 Incidence of breast cancer in the Netherlands 1985'5 
Age (years) 
< 30 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85 + 
Number 
of patients 
52 
180 
385 
543 
680 
715 
760 
914 
845 
886 
698 
473 
290 
Incidence f 
woman-y 
1. 
32 
66 
123 
173 
191 
209 
253 
283 
324 
315 
318 
279 
Total 7421 101 
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'Lead time' 
For tumours detected at screening the diagnosis of breast cancer is advanced. 
In the absence of screening the disease would be diagnosed later, viz. upon 
presentation of symptoms. The length of time by which the diagnosis is 
advanced, is called 'lead time'. In order for a screening programme to be 
successful, a substantial proportion of breast cancer cases has to be detected 
during the preclinical phase and with sufficient lead time. Only then will 
treatment be more effective in terms of additional years of life or breast cancer 
mortality reduction in comparison with a situation where no screening pro-
gramme is implemented. 
Lead time estimates obtained under certain assumptions regarding carcinoma 
growth rates and mammographie sensitivity turn out to be lower for screen-de-
tected carcinomas diagnosed in patients younger than 50 years than in older 
patients.51819 
Growth rate. There are few studies on the growth rate of primary breast 
cancer. They indicate that growth rates are higher in younger than in older 
patients.1923 Consequently, given the same frequency of screening, in younger 
women relatively more cancers will be diagnosed in the interval between a 
negative screening examination and the scheduled subsequent screening exam-
ination. Patients with these so-called interval cancers have received less bene-
fit, if any, from screening, so the expected reduction in mortality will be 
lower for younger women. Given the same quality of mammography, only 
more frequent screening will reduce the proportion of interval cancers.24 
Sensitivity of mammography. Mammographie detectability of cancers in the 
preclinical phase is partly determined by the density of the surrounding 
mammary gland tissue and the type of tumour. The proportion of women 
having a relatively large amount of mammary gland tissue and dense 
parenchyma decreases with age.25·26 Due to the higher density of breast tissue 
in younger women, cancers may not be detectable by mammography until they 
have reached an advanced stage. If so, a larger proportion of screen-detected 
cancers will prove incurable upon detection. This implies a lower breast 
cancer mortality reduction in younger women. More frequent screening will 
reduce the number of interval cancers. This is not to say, however, that the 
lead time for patients with screen-detected cancers will then be enough for 
them to benefit from screening.27 
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'Diagnostic threshold'. If younger women are more aware of the relevance of 
early diagnosis of abnormalities in the breast than older women are, the diag-
nosis of breast cancer in the absence of screening will be made at an earlier 
stage in younger women. The result will be a positive correlation between age 
and stage at diagnosis.28"31 As a consequence, cancers need to be detected even 
earlier if screening is to be effective in younger women. However, it appears 
to be more difficult to detect smaller tumours in younger women. 
Prognosis 
In various studies, the relation between a woman's age at breast cancer diag-
nosis and prognosis is addressed. Some large-scale studies show that the 
disease has a more favorable prognosis, expressed as 'relative survival' or 
'percentage cured', in younger or premenopausal women.32"3'' Prognosis 
remains more favorable after adjustment for disease stage.2930 Apart from 
favorable disease stage, better host resistance to the developing malignancy 
can be an explanation for the better prognosis in younger women. Another 
explanation can be found in a different biology of the tumours.35 
Older women with breast cancer will die from the disease sooner than 
younger patients. As younger patients live longer with breast cancer, a long 
delay is expected before any reduction in breast cancer mortality due to screen-
ing women under the age of 50 will become apparent. 
When screening postpones death, two alternatives can arise: the patient 
either dies from breast cancer at a later point in time or dies from another 
cause. As older women have a higher probability to die from a competing 
cause of death in the prolonged lifetime, a reduction in mortality from breast 
cancer is likely to emerge. 
By contrast, younger patients will still die from breast cancer, be it later on, 
if they are not cured. It is therefore more appropriate to express the effect of 
screening as the number of years of life gained rather than as a reduction in 
breast cancer mortality. 
DISCUSSION 
Several researchers doubt the efficacy of screening women under age 50,2 and 
some even do so for women above age 50.36"39 Others recommend more aggres-
sive and/or more frequent screening for women younger than 50 years of age, 
in particular once every year instead of once every 2 years.24''0·41 The ongoing 
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screening projects for younger women show only minor short-term effects, if 
any, on the mortality from breast cancer. It is questionable whether these 
projects will permit conclusions to be drawn upon prolonged follow-up. A 
number of factors that hamper evaluation can be summarised: 
- Some women in the control group of the (randomised) screening projects 
were screened mammographically on their own initiative.68,42 In the Malmö 
trial, during the study period 35% of the control group women aged 45-49 
were screened, compared with only 13% of women in the age group 65-69 
years. Therefore, it will be more difficult to demonstrate an effect of screen-
ing in the younger age group. Moreover, not everyone invited to participate 
for screening will attend. In general, compliance by younger women is some-
what higher than by older women.43 
- The frequency of screening in the ongoing projects may be too low to detect 
a substantial proportion of cancers at screening. In the Nijmegen biennial 
screening project, 50% of cancers among the younger participants are 
screen-detected; in older women this proportion is about two-thirds.43 
- The recently reported lowering of the diagnostic threshold in unscreened 
populations will reduce the effect of screening.31·44 
- When the sensitivity of the mammographie screening test is too low to detect 
in younger women a substantial part of the carcinomas in the curable phase, 
mammographie screening can only result in a limited effect on the mortality 
from breast cancer. There is even a risk that women who have been wrongly 
reassured by a negative screening test will exhibit a delay in consulting a 
doctor when symptoms develop. 
In summary: even at longer follow-up, the ongoing screening projects might 
not be able to address adequately the effect of screening younger women. 
From a scientific point of view, mounting a new randomised trial for this age 
group seems to be the best solution. 
In addition to the above-mentioned uncertainties about the effect for younger 
women, the side effects of screening need to be addressed: 
- In the early years of the Nijmegen screening project, only 20% of the 
younger women who were referred because of suspected lesions on the screen-
ing mammogram were diagnosed with breast cancer. For older women this 
percentage was 50.43 Increased experience of the radiologists and the acqui-
sition of more sensitive equipment have improved these percentages in recent 
years. In addition to the more difficult interpretation of the mammograms of 
younger women (due to the denser mammary gland tissue), the lower preva-
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lence of breast cancer in women under age 50 will decrease the positive pre-
dictive value of a screening test for these women. 
- Furthermore, the percentage of intraductal carcinomas among screen-detected 
cancers can be as high as 20% compared with at most 5% in an unscreened 
population. The question regarding overdiagnosis of these in situ cancers 
remains unanswered. Moreover, the proper therapy for these ductal carcino-
mas in situ remains controversial.45 
Because of these side effects of screening and the uncertainty of a beneficial 
effect on mortality from breast cancer, mammographie screening of asymp-
tomatic younger women should not as yet be recommended. 
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ABSTRACT 
The effects on breast cancer mortality seen after 16 years of biennial 
screening of younger women are assessed in this prospective cohort study. 
Since 1975 some 13,500 women, aged 35-49 in 1975, were invited to 
participate in the Nijmegen screening programme comprising a 
mammographie examination every 2 years. By the end of 1990, 75 women 
had died of breast cancer out of the 332 cases diagnosed after the start of 
the screening project. Women from the same birth cohort, living in 
Arnhem, a neighbouring city with a comparable population and without a 
screening project, were used as controls. In this city, 74 breast cancer 
deaths out of 284 cases occurred during the same period. In Nijmegen, 
after 16 years of follow-up, breast cancer mortality showed a non-signifi-
cant reduction of 6% (95% confidence interval: 32% reduction, 29% 
excess). In the relevant period, after a time lag of 10 years from the start 
of the programme, this reduction rose to 20% (95% confidence interval: 
48% reduction, 23% excess). 
No reduction in breast cancer mortality was observed in the first decade 
of screening. For a later period, a shift towards a reduction emerges, but 
the data are as yet inconclusive. 
INTRODUCTION 
Up until now the benefit of periodic breast cancer screening, with modern 
mammography, of women under 50 years of age has been controversial.15 
In the oldest trial, the Health Insurance Plan (HIP) study from the early 
sixties, with 4 annual mammographie examinations combined with physical 
examination, positive results were only observed after a long follow-up of 8 
years.6 Since the HIP study, the quality of mammography has improved con-
siderably, facilitating the detection of more tumours in an early stage of devel-
opment before they have reached an incurable stage. Modern mammography 
therefore might be expected to produce a stronger effect on breast-cancer 
mortality. However, this expectation is lowered by the fact that in most 
ongoing trials the screening interval is at least 2 years, instead of 1 year as in 
the HIP trial. Moreover, mammography is commonly used as the only screen-
ing modality, whereas the HIP study also included palpation. In addition, the 
prognosis of today's breast cancer patients may already have improved to such 
Chapter 3 - Mortality 25 
an extent (e.g., due to early self-detection and a greater cautiousness regarding 
suspect lesions in the breast), that early detection by population screening 
might have a lower effect than anticipated. 
So far, the results of ongoing trials for women under age 50 have been 
inconclusive.710 There appears to be little evidence of benefit, at least in the 
first 10 years after the initial screening examination. A recent analysis of the 
combined Swedish data, a pooling of 5 studies with a screening interval of 
1.5 to 2 years, has shown a non-significant benefit of 13% after a follow-up of 
7 to 12 years." This study suggests that, in this age group, a potential benefi-
cial effect cannot be expected in the first decade after the start of screening. 
In our study, breast cancer mortality in the study population of Nijmegen, 
aged 35 to 49 at the start of the first screening round in 1975 (13,500 
women), has been analysed after 16 years of follow-up. The results are com-
pared with those of the neighbouring city of Arnhem. 
STUDY POPULATION AND METHODS 
In the city of Nijmegen (150,000 inhabitants) a population-based biennial 
screening programme for breast cancer was set up in 1975.'2 Single-view 
mammography was carried out as the only screening procedure every 2 years. 
In the first screening round, all women born in the period 1910-1939 were 
invited. The present study is restricted to women born in 1925-1939, aged 
under 50 at January 1, 1975. For the "date of entry" into the study the date of 
first invitation was taken. In the present analysis, women who moved into the 
area of Nijmegen were also included. This immigration was approximately 1 % 
yearly. The end of the study period was set as the date of death, the date of 
moving out of Nijmegen, or the end of 1990. By this time 8 screening rounds 
had been carried out. The attendance rate was 87% in the first screening 
round and stabilized at about 65% after the fourth round. 
The control group consists of women of the city of Arnhem. This neigh-
bouring city, 15 miles distant from Nijmegen, also has some 150,000 inhabi-
tants. The date of entry into the study for a woman from the control group 
was considered to be the date midway through the first screening round in 
Nijmegen, i.e. January 1, 1976, or, alternatively, the date when she moved 
into Arnhem. The follow-up period ended upon death, upon moving out of the 
city or by the end of 1990. Because no information on an individual level was 
available, mid-year estimates for woman-years at risk for birth cohort 
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1925-1939 were calculated from the official census statistics, published yearly 
by the Dutch Central Bureau of Statistics. 
Information about breast cancer deaths subsequent to diagnosis after entry 
into the study was obtained by a review of the medical files of the deceased 
patients. 
Since 1975, data on all Nijmegen patients diagnosed as having breast cancer 
in either of the Nijmegen hospitals have been carefully recorded by the local 
cancer registry of the Departments of Diagnostic Radiology and Pathology, 
resulting in a number of 332 patients diagnosed with primary breast cancer 
between entry into the study and the end of 1990. The list of all patients 
diagnosed up to the end of 1988 was submitted to the local registrar's office 
for vital status assessment at December 31, 1988. Since the beginning of 1989 
the local registrar's office has supplied us weekly with all the dates of migra-
tions and deaths among Nijmegen women bom before 1940. All clinical 
information concerning the dead patients was gathered to ascertain the cause of 
death, i.e., breast cancer or other. Breast cancer was considered to be the 
underlying cause of death when distant metastases had been reported prior to 
death and competing causes of death could be ruled out. 
For the control population of Arnhem the Carcinoma Working Group com-
posed a list of 284 patients with primary breast cancer diagnosed since 1976. 
The same procedure and criteria for assessing the cause of death were applied 
in both cities. 
The breast cancer mortality rate ratio with 95% confidence interval of the 
Nijmegen versus Arnhem study populations was calculated. 
RESULTS 
From the start of the screening project until the end of 1990, a total of 
332 breast cancer patients, including 38 with ductal carcinomas in situ, were 
diagnosed in Nijmegen. Of these cancers, 38% were detected by screening, 
36% appeared in the interval between screenings and 25% were found in 
women who had been invited for screening but had not responded to the last 
invitation (Table 3.1). By the end of 1990, 29 patients had left Nijmegen and 
82 had died. In Arnhem, in the same birth cohort and calendar period, 284 
patients, of whom only 4 were known to have intraductal carcinoma, were 
diagnosed. During the study period 14 patients had moved away from Arnhem 
and 84 had died. For 3 Arnhem patients (who died in 1977, 1982 and 1986) 
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the cause of death could not be assessed. Breast cancer was considered to be 
the underlying cause of death of 75 patients in Nijmegen and 74 patients in 
Arnhem. Three-quarters of the deaths from breast cancer in Nijmegen 
occurred in women whose tumour had been diagnosed in the interval between 
screenings or in women who had not responded to the last screening invita-
tion. Nevertheless, as many as one-quarter of the deaths occurred in women 
whose carcinoma had been detected at screening. Compared with Arnhem, 
Nijmegen showed a non-significant 6% decrease in the cumulative number of 
breast cancer deaths (cumulative relative risk = 0.94; 95% confidence interval 
0.68-1.29). 
TABLE 3.1 Cumulative breast-cancer incidence and mortality rate in Nijme-
gen and Arnhem among patients from birth cohort 1925-1939 
diagnosed after the start of the screening project in Nijmegen 
until the end of 1990 
Number of primary breast cancers 
Screen-detected 
Interval 
Non-participant 
Moved away from the city 
Died from causes of all kinds 
Died from breast cancer 
Screen-detected 
Interval 
Non-participant 
Nijmegen, after 
entry 
332 
128 (38%) 
119 (36%) 
85 (25%) 
29 
82 
75 
19 (25%) 
28 (37%) 
28 (37%) 
Arnhem, after 
January 1, 1976 
284 
14 
84 
74 
Woman-years 166,307 154,103 
Breast-cancer mortality rate 
(per 100,000 woman-years) 45.1 48.0 
Rate ratio 0.94 
95 % Confidence interval 0.68-1.29 
28 
Cumulative number of breast cancer deaths 
per 100,000 woman years 
Calendar year 
FIGURE 3.1 Cumulative breast cancer mortality rate in Nijmegen (—) and 
Arnhem (—) among patients from birth cohort 1925-1939 
diagnosed after the start of the screening project in Nijmegen 
Figure 3.1 shows the cumulative breast-cancer mortality in the 2 cities for 
patients diagnosed after the start of the screening project in Nijmegen. Previ-
ous studies have suggested that no effect of screening can be expected in the 
first 10 years after initiation of screening; we therefore considered the 
breast-cancer mortality rate ratio for 3 time intervals (1976-1980, 1981-1985, 
1986-1990) specified separately in Table 3.2. After a time lag of 10 years 
from the start of the programme, a non-significant reduction in breast-cancer 
mortality of 20% was found (relative risk = 0.80; 95% confidence interval 
0.52-1.23). 
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TABLE 3.2 Breast cancer mortality in Nijmegen and Arnhem among patients 
diagnosed after the start of the screening project in Nijmegen 
according to calendar period and birth cohort 
Period Birth 
cohort 
Woman-years Breast-cancer deaths Rate ratio 
Nijmegen Arnhem Nijmegen Arnhem 
1976-1980 1935-1939 18,742 16,610 2 0 
1930-1934 19,062 17,389 4 5 
1925-1929 18,962 18,811 6 3 
1925-1939 56,766 52,810 12 8 1.40(0.57-3.40) 
1981-1985 1935-1939 18,720 16,536 
1930-1934 18,917 16,987 
1925-1929 18,459 18,225 
8 
8 
8 
2 
7 
12 
1925-1939 56,096 51,751 24 21 1.05 (0.59-1.89) 
1986-1990 1935-1939 17,937 16,120 
1930-1934 18,026 16,237 
1925-1929 17,482 17,186 
10 
16 
13 
17 
16 
12 
1925-1939 53,445 49,542 39 45 0.80(0.52-1.23) 
DISCUSSION 
This study addresses the issue of long-term breast-cancer mortality in young 
women who had the opportunity of mammographie screening once every 
2 years. 
Due to the non-randomized design of the Nijmegen programme, special 
attention was given to potential sources of bias. Of major concern was the 
comparability of the populations in the 2 cities with respect to risk of 
breast-cancer death. To evaluate comparability, population mortality rates of 
breast cancer in the pre-screening period in both cities were assessed. In the 
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period 1970-1974, Nijmegen appears to have had a lower mortality in the 
35-64 age group (rate ratio = 0.68; 95% confidence interval 0.48-0.96).13 
However, this apparently lower risk for breast-cancer death does not persist in 
the period 1975-1979, the first years of the programme.14 Taking these figures 
into consideration, no unambiguous conclusion can be drawn regarding the 
"baseline" differences in breast-cancer mortality in the eighties for cases 
diagnosed after the start of the screening project. Any difference in breast-can-
cer mortality between the 2 cities in favour of Nijmegen which is not due to 
intervention diminishes the reduction attributable to screening. 
In the whole 16-year period of follow-up (1975-1990, that is from the start 
of screening to the end of follow-up) an 8% excess of breast-cancer cases was 
observed in Nijmegen. Higher incidence is to be expected from any screening 
programme for breast cancer because of the advanced detection through screen-
ing and increasing incidence with age.15 In younger women the detection of 
many ductal carcinomas in situ (DCIS) may also contribute to an increase in 
incidence. In the present study 22% (N = 28) of the screen-detected cancers 
are DCIS. The likelihood of these DCIS progressing to clinical disease in the 
absence of screening is unknown. In our study, part of the excess may also be 
ascribed to an under-recording of breast-cancer cases in the first years in 
Arnhem. The Carcinoma Working Group, Arnhem, has been operative since 
1979. In the 3-year period prior to 1979 the breast-cancer incidence rate in the 
younger age-groups was 23% less than might have been expected on the basis 
of the incidence rates in the overall Dutch population as obtained from the 
Central Bureau of Statistics. Between 1979 and 1988 the incidence rate in 
Arnhem was the same as that in the total Dutch population. A random 
under-reporting of 23 % in the first 3 years in Arnhem would have yielded 4 
more breast cancer deaths, increasing the cumulative breast cancer mortality 
reduction from 6% to 11% and, in the post-10-year observation period 
1986-1990, from 20% to 21%. 
Determination of the underlying cause of death can be subject to a (differen-
tial) misclassification. In the breast-cancer patients of this younger age group, 
however, competing causes of death were involved only in a minor proportion 
of the deceased patients. In the overview of the Swedish randomized trials the 
mortality reduction in the whole study population was similar, irrespective of 
the end-point used for evaluation (i.e., "breast cancer as underlying cause of 
death" or "breast cancer present at death").11 
The deaths occurring during the first years of a screening programme will 
mainly concern patients whose disease was already at an advanced stage at the 
Chapter 3 - Mortality 31 
time of diagnosis. It is thus reasonable to assume that the effect of screening 
for breast cancer is delayed in any age group. One may expect, however, a 
longer delay for younger women because of (1) the better relative survival of 
younger patients with breast cancer16 and (2) an apparently longer lead time of 
cases of DCIS which are detected more frequently in this age group. In the 
more relevant observation period, beginning one decade after the start of the 
programme, i.e. the period 1986-1990, our study showed a promising 20%, 
though still non-significant reduction in mortality. One could advance the idea 
that this reduction is the effect of the screening of those women who passed 
the age of 50 during the observation period, but this supposition is not sup-
ported by the observations in women of birth cohort 1925-1929 (aged 45 to 49 
at the start), among whom no mortality reduction during the period 1986-1990 
was observed. 
Taking into account all the available information and possible sources of 
bias, we conclude that biennial mammographie screening of women under the 
age of 50 in Nijmegen has not resulted in a reduction in breast-cancer mortal-
ity during the first decade. For a later period, a shift towards a reduction 
emerges, but the data are as yet inconclusive. 
All women in the 1925-1939 birth cohort have now passed the age of 50 
and they will be screened biennially as part of a nation-wide screening pro-
gramme, which includes Arnhem as well. If longer follow-up reveals that the 
reduction in breast cancer mortality continues to be present, this could be the 
effect of screening the younger age group in Nijmegen. 
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ABSTRACT 
Currently, there have been no reports of clear-cut beneficial effects of 
regular screening with mammography at a mean screening interval of 
2 years in women younger than 50 years of age. It may be that, because of 
a higher growth rate of breast cancer, more frequent screening is neces-
sary if any effect is to be observed in this age group. However, good 
quantitative estimates for the growth rate in different age groups are 
lacking. 
The study group consisted of cancers diagnosed in women who partici-
pated in a screening program with serial mammography available. The 
growth rate, expressed as the tumor volume doubling time, was calculated 
on the assumption of exponential growth. The analysis was based, not only 
on the increase in tumor volume for cancers with at least two mammo-
grams showing a measurable tumor nucleus shadow (n = 85), but also on 
censored values, calculated for cancers showing no growth (n = 6) and for 
cancers showing only a measurable tumor nucleus shadow on the 
mammogram at diagnosis (n = 109). In calculating these latter growth 
rates, the density of the breast parenchyma was taken into account. 
The median volume doubling time of the primary breast cancers diag-
nosed in women aged 50-70 years was 157 days (95% confidence limits, 
121-204 days). This was significantly longer than in women younger than 
50 years of age at diagnosis (80 days; 95% confidence limits, 44-147 days). 
Primary breast cancer in women older than 70 years of age at diagnosis 
grew even more slowly (median, 188 days; 95% confidence limits, 
120-295). 
To observe a beneficial effect of screening, if any, for women younger 
than age 50 years, more frequent screening than in the older age group is 
necessary. 
INTRODUCTION 
There are few studies on the growth rate of primary breast cancer, and in 
particular, quantitative estimates of the growth rate in different age groups are 
lacking. The growth rate can be estimated in vivo from the increase in the 
tumor shadow using serial mammograms. 
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In breast cancer screening programs, serial mammograms are available for 
all "incident" cancers detected among the screenees. In addition to these 
screen-detected cancers, there are the so-called interval cancers, i.e., cancers 
diagnosed in the interval between a negative screening examination and the 
subsequent scheduled screening examination. Interval cancers could occur 
because they were missed at the previous screening examination or because the 
tumors, initially too small to be detected by screening, had a high growth rate. 
Part of the interval cancers that occurred as a result of a high growth rate 
would be detected in an earlier stage at a screening examination if screening 
were done more frequently. The issue of screening frequency is especially 
relevant for women younger than age 50 years because no clear breast cancer 
mortality reduction has been demonstrated in this age group so far and rela-
tively high interval cancer rates have been observed.1,2 
The current study analyzes the dependence of the breast cancer growth rate 
on age. In calculating this growth rate, the density of the breast parenchyma is 
taken into account because the radiologically detectable size of the breast 
cancer will be influenced by the breast tissue pattern, which is age dependent.3 
PATIENTS AND METHODS 
Data collection 
Serial screening mammograms were obtained from the ongoing breast cancer 
screening program conducted in Nijmegen, the Netherlands, since 1975.2 In 
the beginning, lateromedial view mammography was performed. Since August 
1981, mediolateral oblique single-view mammography has been used. The 
study group consisted of all cancers diagnosed among participants in the 
program in the period from the introduction of the mediolateral oblique projec-
tion in 1981 to the end of 1990. During this period, nearly 30,000 women 
were invited for screening every other year. The attendance rate among 
women younger than age 50 years was 70%. Compliance was 60% among 
women 50-70 years of age and 20% among women older than age 70 years. 
For cancers detected at screening or diagnosed between screening exami-
nations, previous screening mammograms were reexamined by one radiologist 
(J.H.) to determine whether, in retrospect, a tumor could be identified and 
measured. The review revealed that, in several of the interval cancers, a 
tumor nucleus shadow could be identified in the "negative" previous 
mammogram. Other interval cancers, although visible radiographically at the 
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time of the diagnosis, showed no suspect lesions on a previous screening 
mammogram. These cancers that were below the detection threshold on a 
prior breast evaluation became symptomatic and were discovered before the 
next examination. They were masked in some way at the previous examination 
or were newly grown, which implied a high growth rate. This retrospective 
approach was used in a similar way to that reported in an earlier study.4 An 
analogous review of earlier screening mammograms was also carried out for 
the screen-detected cancers. 
The patients were eligible if at least two mammographie examinations with 
the mediolateral oblique projection were available. Radiographically occult 
cancers were excluded from the current study (16% of the interval cancers in 
the Nijmegen program5). The resultant study group comprised 289 cancers. 
The age at diagnosis ranged from 41-84 years (mean, 62 years). 
Fifty-three cancers were detected because of microcalcifications (η = 47) or 
other indirect signs (n = 6) such as reactive fibrous tissue, nipple retraction, 
or diffuse pattern. At the time of diagnosis of these cancers, no tumor nucleus 
shadow could be observed on the mammograms. The analysis of the growth 
rate was based on the remaining 236 cancers with measurable tumor nucleus 
shadows on their mammograms at diagnosis. 
The tumor diameter was measured in the longest axis of the tumor, and a 
second maximum diameter was measured perpendicular to the longer axis. The 
mammographie volume was estimated using the formula for oblate spheroids 
3 2 2 2 2 2 
where a and b were the perpendicular diameters. 
Five cancers showed no growth in the interval between two measurements 
of the same tumor. The respective lengths of the intervals were 2 months, 
5 months, and for three cancers, 2 years. Based on two measurements of the 
same tumor, with an interval of 6 months, one cancer showed a regression of 
the tumor. However, this decrease could also be explained by measurement 
error, and therefore, no growth was assumed. 
Excluding these six tumors, the time interval between the two mammogra­
phie examinations revealing a shadow for the same tumor ranged from 6 
months to 5 years; in 79% of the cases, the interval ranged between 1-3 years. 
For the 145 cancers with only one mammogram showing a tumor nucleus 
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shadow, the time interval since the last mammogram without a shadow ranged 
from 2 months to 9 years; it was within 1-3 years in 70% of these cancers. 
Calculation of growth rate 
The growth rate, expressed as tumor volume doubling time (DT), was calcu-
lated on the assumption of exponential growth (reflecting a fixed tumor vol-
ume DT) as follows: 
DT = ^ 2 
ß 
where ß was the slope of the regression line of the logarithm of the tumor 
volume versus time. 
When at least two mammograms with a measurable tumor nucleus shadow 
were available, the actual DT could be estimated directly from the increase in 
tumor volume. If there was no observable growth, the DT was certainly 
longer than the time interval between the two measurements, yielding a 
right-censored value for the actual tumor DT. 
In cancers with serial mammograms in which a tumor nucleus shadow could 
only be observed on the mammogram at diagnosis and not on the previous 
screening mammogram, the size of the tumor mass at the time of the previous 
mammogram was supposed to be too small to be visible radiographically. 
Radiographically nonoccult cancers with a volume larger than a certain thresh-
old value were likely to be visible on the mammogram. For cancers with a 
tumor nucleus shadow only on the mammogram at diagnosis and not on the 
previous screening mammogram, the actual tumor volume DT must be smaller 
than the DT based on the threshold volume at the time the previous 
mammogram was made and the volume at diagnosis, which yielded a left-cen-
sored value for the actual tumor DT. 
In technically perfect mammograms, invasive breast cancers of a diameter 
of approximately 5 mm in a breast with low density could still be detected 
radiologically by most investigators. In practice, a larger threshold value, 
depending on the density of the breast, would be more realistic. The density of 
the breast was recorded according to Wolfe3 classification. In dense breasts 
with P2 or Dy patterns of this classification, the threshold value for visibility 
would be larger than for the N1 and PI patterns. 
The values for the threshold volume were obtained as follows. For cancers 
with at least two mammographie pictures with a measurable tumor nucleus 
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shadow and a previous mammogram without a shadow (n = 44), the expo-
nential growth was extrapolated to the time the previous mammogram was 
made. This extrapolation showed that tumors with a volume larger than 
65 mm3 (corresponding with two perpendicular diameters of 5 mm) could have 
been missed, even in breasts with N1 or PI patterns. However, nearly all 
tumors that were not visible on a mammogram had an extrapolated volume 
smaller than 524 mm3 (corresponding with two perpendicular diameters of 
10 mm). Tumors with a volume larger than 1767 mm3 (corresponding with 
two perpendicular diameters of 15 mm) would not have been missed. Accord-
ingly, for breast tissues of N1 or PI patterns, we assumed that if no shadow 
could be seen on the mammogram, the tumor volume had to be smaller than 
524 mm3. For dense breasts with a P2 or Dy pattern, the threshold volume for 
visibility was assumed to be larger, i.e., 1767 mm3. 
Statistical analysis 
The object of this study was to obtain quantitative estimates for the growth 
rate depending on the age at diagnosis. Three age groups were distinguished: 
younger than 50, 50-70, and older than 70 years of age at diagnosis. 
Assuming a normal distribution for the logarithm of the tumor volume DT 
with the same standard deviation in each age group, the geometric mean of the 
DT in the three age categories could be estimated with the maximum-likeli-
hood method. The contribution to the likelihood function for the censored DT 
was obtained under the assumption of independent censoring. The standard 
deviation after logarithmic transformation, which could be interpreted as the 
coefficient of variation, was used to calculate the 68% range of the tumor 
volume DT to give an indication of the variation. 
RESULTS 
In Table 4.1, for each age group, the proportion of radiographically nonoccult 
cancers showing a tumor nucleus shadow on the mammogram at diagnosis is 
given. In Table 4.2, the numbers of (censored) observations used for estimat-
ing the parameters of the log-normal distribution for the volume DT are given. 
For 36 cancers, the mammographically determined tumor volume at diagnosis 
was smaller than the threshold volume for the previous mammogram, and 
therefore, no upper value for the DT could be calculated. The remaining 
109 cancers with only one shadow yielded a left-censored value for the DT. 
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TABLE 4.1 Tumor shadow or indirect signs of tumor on mammogram at 
diagnosis 
Age at 
(yr) 
< 50 
50-70 
> 70 
Total 
diagnosis Tumor nucleus 
shadow 
32 (70%) 
154 (82%) 
50 (91%) 
236 (82%) 
Indirect signs 
(calcifications or other) 
14 (30%) 
34 (18%) 
5 (9%) 
53 (18%) 
Total 
46 
188 
55 
289 
TABLE 4.2 Number of observations used for analyzing the tumor volume 
doubling time 
Age (yr) 
< 50 
50-70 
> 70 
Total 
Not 
censored 
9 
58 
18 
85 
Right 
censored 
0 
5 
1 
6 
Left 
censored 
17 
67 
25 
109 
Drop out* 
6 (19%) 
24 (16%) 
6 (12%) 
36 (15%) 
Total 
32 
154 
50 
236 
* Only on the diagnostic mammogram was a tumor mass visible with a volume 
smaller than the threshold volume; so no censored value for the doubling time 
could be calculated. 
TABLE 4.3 Tumor volume doubling time of primary breast cancer according 
to age 
Age at diagnosis (yr) Geometric mean in days 
(95% confidence limits) 
68% range" 
< 50 
50-70 
> 70 
80 (44-147) 
157 (121-204) 
188 (120-295) 
24-273 
46-533 
55-640 
Likelihood ratio test: Ρ = 0.06 
Sixty-eight percent of the tumor volume doubling times are between the present­
ed limits: 16% is smaller than the lower limit, 16% is larger than the upper 
limit. 
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In Table 4.3, the geometric mean and the 68% range of the volume DT of 
the primary breast cancer for different age groups are given. The median 
volume DT of cancers diagnosed in women aged 50-70 years was almost twice 
that of cancers diagnosed in women younger than 50 years of age (P = 0.04, 
by Wald test; 95% confidence limits for the ratio of the medians, 1.03-3.70). 
DISCUSSION 
A basic assumption underlying the conclusions here presented is the expo-
nential growth pattern of cancers of the breast during the preclinical phase of 
the tumor. Collins et al.6 were the first to introduce the idea that the growth of 
malignant tumors in humans is exponential and that the rate of growth can be 
described by the DT of the tumor. 
The more realistic hypothesis, i.e., that the DT tends to increase as the 
tumor grows, is expressed by the Gompertz function. Too little information 
for estimating the parameters of the Gompertz function was available, but in 
the early phase of development, the Gompertz function is identical to an 
exponential function. In our study, three pretreatment mammograms were 
available for 17 patients. An increase in tumor volume DT between the second 
and third mammograms compared with the DT between the first and second 
mammograms was observed in eight patients; in the other nine, the DT 
decreased or remained the same. 
The earliest studies on growth rates of mammary carcinoma measured from 
successive mammograms were based on a limited selection of cases.7"9 More 
recent studies (Table 4.4) based on cancers detected in a screened population 
excluded patients in whom no tumor shadow was measurable in previous 
screening mammograms, leading to an underestimation of the growth rate.10"13 
Studies based on inpatients in whom serial measurements, clinically or 
mammographically, were available because of a delay in treatment showed 
faster growing tumors.14"16 The current study confirmed the positive correlation 
between age and tumor volume DT that was demonstrated in other 
studies.12·14·16"18 
Not included in the analysis of the growth rate were the cancers with no 
measurable tumor shadow on the mammogram at diagnosis. A large part of 
these 53 cancers, detected by indirect signs, were ductal carcinoma in situ 
(n = 23). 
Chapter 4 - Growth rate 41 
TABLE 4.4 Measurements of the breast tumor volume doubling time presented 
in the literature 
Reference 
Lundgren10 
Heuser et al." 
von Fournier et al.12 
von Fournier et al.13 
Kuroishi et al.17 
Kusama et al.14 
Galante et al.15 
Tabbaneetal.16 
Subjects 
13 screened patients 
32 screened patients 
147 screened patients 
200 patients 
122 screened patients, 
20 inpatients 
199 inpatients 
196 inpatients 
75 inpatients 
Mean 
doubling time 
190 
268 
9 
220 
220 
174 
days 
days 
no growth 
days 
days 
days 
3.5 months 
2 
115 
months 
days 
Mean age at 
diagnosis 
(yr) 
61 
55 
< 45 
57 
48 
Cancers with no measurable tumor shadow on the previous mammogram 
and too small a tumor volume on the mammogram at diagnosis had to be 
excluded from the analysis of growth rate because no left-censored value could 
be calculated. Slow-growing tumors might be somewhat overrepresented 
among these cancers. They were, however, equally distributed among the age 
groups, especially in those younger than 50 years of age compared with those 
50-70 years of age (19% for the < 50 group, 16% for the 50-70 group, and 
12% for the > 70 group). Therefore, the exclusion of these cancers cannot be 
an explanation for the demonstrated higher growth rate in younger women. 
The method of measuring the tumor nucleus shadow in a mammogram was 
subject to various sources of error.12 Varying parts of the nucleus density seen 
on the mammogram consisted of stroma; therefore, the measurements might 
not only concern tumor cells. The nucleus shadow in most cases could not be 
precisely defined, i.e., measurement of the tumor was subject to error. This 
measurement error was reduced by using the same mediolateral oblique pro-
jection for all mammograms and by having the measurements carried out by 
one experienced radiologist. A systematic measurement error of the diameters 
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of the tumor shadow in serial mammograms affected the growth rate to a 
lesser extent because calculation of the growth rate considered only of the 
increase in growth from one mammogram to the next. The influence of the 
measurement error on the calculation of the tumor volume DT was small in 
comparison with the large overall variation in DT. Despite the great variation 
in volume DT, partly as a result of measurement error, a difference in the 
median volume DT between age groups could be demonstrated. 
Relatively high interval cancer rates had been observed for women younger 
than age 50 years.12 Improved imaging techniques suited for the younger 
breast with a denser parenchyma should reduce the number of missed cancers. 
However, because of the higher growth rate, the screening interval has to be 
shortened to reduce the number of interval cancers in this age group. A more 
frequent screening schedule had already been proposed by others.119 This is 
not to say, however, that more frequent screening will necessarily lead to a 
clear mortality reduction in this age group. First, this depends on the point of 
transition in tumor development between the curable and the incurable phases, 
which may be different for different age groups.20 Second, the use of mammo-
grams at more frequent intervals causes a greater dose of radiation to be 
administered. 
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ABSTRACT 
The sensitivity of the mammographie screening test in the biennial screen-
ing program of Nijmegen is assessed by analyzing the occurrence of inter-
val cancers, i.e. cancers surfacing clinically in the interval between a 
negative screening examination and the subsequent scheduled examination. 
The difference between the observed number of interval cancers and the 
expected number of clinically manifest cancers in the absence of screening 
for the interval period reflects the number of cancers detected by screen-
ing. The expected number should be limited by the number of those can-
cers that were not detectable at the time of the screening examination 
because their size was under the threshold of mammographie detectability 
(5 mm). In contrast to other sensitivity studies we took these 'fast 
growing' cancers into consideration, the numbers of which are estimated 
in each of the six-month periods of the two-year interval using age-specific 
tumor volume growth rates for three age groups: < 50, 50-69 and ä 70 
years. 
In patients under age 50, the sensitivity was 64% for cancers which 
would become clinically manifest within one year after screening. This 
sensitivity was lower than those obtained for the 50-69 and ^ 70 age 
groups, being 85% and 80%, respectively. For cancers that would become 
clinically manifest 12-18 months after screening, sensitivity decreases to 
22% in the under age 50 group, and to 56% and 65% in the two above age 
50 groups, respectively. 
We conclude that even when adjusted for growth rate, the mammogra-
phie screening test has a poor performance in the under age 50 group. 
INTRODUCTION 
The debate about the age-range for effective mammographie screening is still 
going on. It is generally accepted that breast cancer screening by periodic 
mammographie examination in women aged 50-69 can reduce breast cancer 
mortality by 20-40%.u The beneficial effect of screening for women younger 
than 50 years of age remains controversial.2 There appears to be little evi-
dence of benefit. This may be partly explained by a higher growth rate of the 
tumor in younger women and a lower sensitivity of the mammographie screen-
ing test. These two factors result in a relatively high number of interval can-
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cers, i.e. cancers diagnosed in the interscreening interval following a negative 
examination. 
The age-dependent tumor growth rate was studied in an earlier paper.3 The 
sensitivity of the mammographie screening test is the subject of this paper. 
The concept of sensitivity is worked out as the probability that the mammo-
graphie screening test correctly identifies an individual who is in the 
preclinical phase of the disease.4 The sensitivity of mammography is adversely 
influenced by factors such as suboptimal imaging, incorrect positioning, insuf-
ficient compression of the breast, deviant location of the tumor, increased 
parenchymal density of the breast as well as by the observer error. Review of 
the last screening mammogram before diagnosis reveals that depending on the 
length of the screening interval 20-30% of the interval cancers were missed 
because of observer error.5"7 
The sensitivity of mammography or its complement, the proportion of 
false-negative mammographie tests, are not directly estimable. In particular, 
the number of individuals with a negative screening test who in fact have the 
disease, is not known. Part of the preclinical cancers that are not detected at a 
screening test can subsequently manifest as interval cancers and can be 
regarded as cancers missed by the test. However, not all of the interval can-
cers are truly 'missed' cases. Some of them are not detectable because their 
size is under the threshold of the mammographie detectability (5 mm) and they 
surface in the interval period because of a high growth rate. Based on the 
occurrence of all interval cancers, previous investigators have attempted to 
estimate the sensitivity of a breast cancer screening test by a variety of 
methods, such as the 'detection method' (ratio of screen-detected cancers to 
screen-detected plus interval cancers) and the 'proportional incidence method' 
(1 minus ratio of interval cancers and expected cancers in absence of screen-
ing).8"12 Both methods may lead to biased estimates as they fail to take into 
consideration the group of fast growing interval cancers with a sub-mammo-
graphic-threshold-size at the time of the negative test.2·12·13 
In the present study, we made a correction by limiting the number of inter-
val cancers by those cases that were apparently not in a detectable preclinical 
phase (less than 5 mm in size) at the time of the screening test. The sensitivity 
of the mammographie screening test has been determined for tumors which 
would, in the absence of screening, arise clinically in one of the four succes-
sive six-month periods of the two-year interval following the screening exami-
nation, for women of three age groups, viz. < 50, 50-69 and > 70 years of 
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age at the time of the last invitation to participate in the screening program 
before breast cancer was diagnosed. 
Data were used of the occurrence of interval cancers in the biennial screen-
ing project in Nijmegen, The Netherlands. 
STUDY POPULATION AND METHODS 
Study population 
In the city of Nijmegen (150,000 inhabitants) a population-based biennial 
screening program for breast cancer was set up in 1975.14 Women were 
invited to participate in the program by birth cohort. From the first screening 
round onward, all women aged 35-64 at January 1, 1975 (n = 23,000) were 
invited for screening. In the subsequent screening rounds, older women 
(n = 7,700) were also invited. At the start of round 4 in 1981, all the invited 
women had reached the age of 41. In round 5, an additional cohort of women 
40 years of age or older at that time was invited. In round 6 and round 7, 
respectively, the invited group was further extended with all the women who 
reached the age of 40 in 1985 and 41 in 1987, respectively. Non-attenders 
were still invited to all subsequent rounds. The attendance rate stabilized at 
about 70% for women younger than 50 years of age and at about 60% for 
women aged 50-69. In the group of women aged 70 years or older, less than 
25% of the invited women participated in the later rounds (rounds 4-8). 
Single-view mammography was carried out as the only screening modality 
every two years. In rounds 1-3 a single lateral-medial view of each breast was 
taken. From round 4 onward, a mediolateral-oblique view was taken. By the 
end of 1992, nine screening rounds had been carried out. 
Since 1975, data on all Nijmegen patients with primary breast cancer have 
been carefully recorded by the local cancer registry of the Department of 
Diagnostic Radiology and the Department of Pathology. Also the participation 
patterns of all individual women invited for screening have been recorded. 
The present study includes the interval cancers that were diagnosed after the 
introduction of the mediolateral-oblique view in round 4 (1981, 1982) and 
before the invitation to round 9 (1991, 1992). The number of interval cancers 
in a given time period after a negative screen is compared with the number of 
cancers that is expected to occur in the absence of screening. Applying 
age-specific (five-year age groups) incidence rates from a comparable refer-
ence group to the number of person-years of the screenees yields the expected 
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numbers. After a negative screening test, each woman experiences person-time 
of follow-up during which she is at risk of breast cancer, until the invitation to 
the next test or until death or moving out of the city. The expected tumor 
incidence in women attending screening can be calculated from the incidence 
in a comparable reference group, adjusted for the incidence rate in the 
non-compliers to allow for possible selection bias.15 For this calculation the 
1981-1988 incidence in Arnhem, a neighbouring unscreened city, was used. 
Assuming independency between screening tests carried out on the same 
woman, the data from the five recent screening rounds (rounds 4-8) were 
pooled. The difference between the actually observed number of interval 
cancers and the expected number of clinically manifest cancers in the absence 
of screening reflects the number of cancers detected by previous screening that 
would otherwise have surfaced too in the screening interval. 
To calculate the sensitivity, the number of potentially detectable preclinical 
cancers present at screening has to be estimated. Some of the observed inter-
val cancers will have been too small at the time of the screening examination 
to be mammographically detectable and will have surfaced clinically in the 
interval period due to a high growth rate. The relative proportion of these 
interval cancers is age related and must therefore be taken into account for the 
age-related sensitivity assessment of mammography. 
Detectable preclinical phase 
In technically perfect mammograms read under optimal circumstances, inva-
sive breast cancers of a diameter of approximately 5 mm in a breast with low 
density should be detected. As soon as the diameter of the tumor has reached 
this size, it is potentially detectable by the screening test and the individual 
enters the detectable preclinical phase of the disease. The mean diameter at 
which symptoms develop and consequently the disease will become clinically 
manifest, is set at 20 mm. The duration of the so defined detectable preclinical 
phase was calculated for three age groups, viz. < 50, 50-70 and > 70 years, 
using age-specific tumor volume growth rates (see Appendix). 
Sensitivity 
To estimate the number of expected cancers in the interscreening period that 
are preclinically present and detectable at screening, the number of unde-
tectable cancers arising because of a high growth rate, the 'new' cases, should 
be subtracted from the total number of expected cancers. The estimate of the 
50 
sensitivity (S) corrected for these 'new' cases, as was suggested by Day,13 (see 
Appendix) is given by 
s= L·^ 
E-E(new cases) 
where О = observed number of interval cancers, E = expected number of 
clinically manifest cancers in the absence of screening and E(new cases) = 
expected number of undetectable interval cancers arising because of a high 
growth rate. 
RESULTS 
Table 5.1 shows the number of screen-detected and interval cancers by age at 
last invitation before diagnosis. In the 40-44 age group with 10,811 screening 
examinations, 18 cancers are detected at screening and 26 interval cancers are 
diagnosed. In the 45-49 age group with 14,309 screening examinations these 
numbers are 26 and 28, respectively. The mean duration of the potentially 
detectable preclinical phase for the different age groups is given in Table 5.2. 
TABLE 5.1 Number of screening examinations in rounds 4 to 8 and number 
of cancers detected at screening or clinically diagnosed in the 
subsequent interscreening period 
Age at 
invitation 
< 50 
50-69 
> 70 
Number of screening 
examination 
25120 
45056 
9286 
Cancer at 
screening 
44 
156 
73 
Interval 
cancer 
54 
96 
31 
Table 5.3 gives the numbers of cases observed and expected if no screening 
had been performed, for the four six-month periods of the two-year interval 
after the screening test, by age at last invitation to participate in the screening 
programme before breast cancer diagnosis. The screen-detected proportion of 
the cancers preclinically present at screening that would have surfaced clinical­
ly within the interval period gives the adjusted sensitivity. In the 50-69 age 
group, 94% of the detectable preclinical cancers which would develop into 
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symptomatic disease of breast cancer within half a year are detected at screen­
ing. The sensitivities of the mammographie screening test to cancers which 
would become manifest г-l, 1-1'Λ and 1Ά-2 years after screening are 75%, 
56% and 32%, respectively. The results in the above age 70 group are com­
parable to those found in the 50-69 age group. The under age 50 group shows 
fluctuating sensitivities of 49%, 82% and 22% for the first three 6-month 
periods, respectively. For the fourth 6-month period after screening no sensi­
tivity was calculated because the expected number of cancers that could have 
been detected at screening was too small, viz. approximately 5. Taking into 
account the Poisson variation in the observed number of interval cancers, no 
statistically significant difference between the sensitivities for the first and 
second six month periods after screening could be demonstrated. A combined 
estimate for the first year following screening results in a sensitivity of 64% in 
the under age 50 group, compared with 85% and 80% in the above age 
50 groups. 
TABLE 5.2 Duration of the detectable preclinical phase' 
Age 
< 50 
50-70 
> 70 
Mean (in years) 
1.9 
3.7 
4.5 
95% confidence limits 
1.0-3.5 
2.9 - 4.8 
2.8-7.0 
Calculated using age-specific tumor volume growth rates (see Appendix). 
DISCUSSION 
A variety of methods for estimating the sensitivity of breast cancer screening 
are described in literature. Irrespective of the methods used, the sensitivity is 
consistently lower for women aged 40 to 49 years compared with women 
older than age 50.2 The methods that use information about the cancers 
detected at screening have to deal with the problem of regression:4·16·17 
mammography detects many in situ cancers, especially in the younger age 
group, but we do not know if they would ever cause symptoms. Our estimates 
and the estimates obtained with the proportional incidence method concern 
strictly the lesions which would proceed to clinical disease. But, the estimates 
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TABLE 5.3 Sensitivity by time since the last screening examination, based on 
the observed number of interval cancers and the expected number 
of clinically manifest cancers in the absence of screening 
Age at last 
invitation 
< 50 Observed (0) 
Expected (£) 
Expected 'new' 
Sensitivity* 
50-69 Observed (0) 
Expected (£) 
Expected 'new' 
Sensitivity* 
> 70 Observed (0) 
Expected (£) 
Expected 'new' 
Sensitivity* 
cases* 
cases" 
cases* 
Interval after screening examination 
< V4 
year 
10 
17.7 
2.1 
49% 
6 
51.8 
3.3 
94% 
2 
14.4 
0.8 
91% 
% - 1 
year 
8 
17.9 
5.8 
82% 
20 
52.0 
9.5 
75% 
6 
14.2 
2.2 
68% 
1 - VA 
year 
16 
18.1 
8.6 
22% 
31 
51.9 
14.7 
56% 
7 
13.8 
3.4 
65% 
VA - 2 
years 
15 
12.6 
7.4 
-
34 
42.5 
15.8 
32% 
9 
11.5 
3.7 
32% 
The expected number of 'new' cases (EP) whose detectable preclinical 
phase starts after the screening examination. 
* Sensitivity = -^2. . 
£-£" 
determined with the proportional incidence method underestimate the sensitiv-
ity because the cancers, which have surfaced because of a high growth rate, 
are not excluded in that analysis. 
Joint estimation of the mean length of the time during which preclinical 
lesions are detectable by screening and the sensitivity yields large simultaneous 
confidence regions.4,16-18·" Estimates obtained from the same data yield equally 
good results with a relatively short detectable preclinical phase and a high 
sensitivity as with a longer detectable preclinical phase and a low sensitivity. 
In our study, the duration of the detectable preclinical phase was estimated 
separately. 
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Although our method of obtaining the mean duration of the detectable 
preclinical phase is quite different from other studies, the resulting estimates 
are quite similar.20"22 Our estimate is based on the growth rate of 'solid' tu-
mors assessed in our previous study.3 For clinically manifest cancers with no 
measurable tumor shadow on the mammogram at diagnosis the same estimate 
was employed. These cancers constitute approximately 10% of the interval 
cancers. 
The expected cancer incidence in the cohort of screened women was calcu-
lated from the incidence in a neighbouring unscreened city, Arnhem, adjusted 
for the incidence rate in the non-compliers. A non-complier is someone who 
was invited to participate but never attended the screening. A special problem 
is formed by those women who attended screening initially but did not re-
spond later on. In our calculations, we assumed that these women, had they 
not been previously screened, would have had the same incidence as the 
regular participants in the absence of screening. Under the alternative assump-
tion that these women would have had the same incidence as the non-com-
pliers, the results for the under age 70 groups change only marginally. For the 
> 70 age group the expected incidence in the screened women would be 
much higher, yielding higher sensitivity rates. The 1981-1988 incidence in 
Arnhem was carefully recorded by the Carcinoma Working Group. In the 
period prior to the screening program (1970-1974), a somewhat lower, 
although statistically non-significant, incidence rate for breast cancer in 
Nijmegen was observed.23 
The observed declining sensitivity in the above age 50 groups as the time 
between screening examination and symptomatic disease lengthens, reflects the 
dependency of the sensitivity of the mammographie test on the size of the 
tumor. Lesions would thus be easier to detect when the time they have to 
progress before surfacing clinically is shorter. In literature, models relating 
sensitivity to cancer development and size are sparse.22·24 The expected declin-
ing trend in sensitivity as mentioned above cannot be inferred in the under age 
50 group presumably because of unstable estimates. The lower sensitivities 
observed in the under age 50 group may be explained by other factors than the 
size of the tumor which co-determine whether or not the preclinical cancer is 
detected. These factors may involve the density of the breast tissue or special 
types of radiologically occult cancers or may be related to the phase in the 
menstrual cycle ('W.J.M. Hrushesky, personal communication'). 
In this younger age group the date of diagnosis could not be advanced by 
more than 18 months and in the second year after screening, the interval 
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cancer rate returned to a level comparable to the expected rate in the absence 
of screening. Therefore, a two-year interval between screens for younger 
women appears to be too long.25 Annual screening in the younger age group 
yields relatively the same interval cancer rate as observed in the above age 50 
groups with biennial screening. This is not to say, however, that annual screen-
ing will simply result in a breast cancer mortality reduction. 
TABLE 5.4 Observed number of interval cancers and expected number of clin-
ically manifest cancers in the absence of screening by five-year 
age groups 
Age at diagnosis 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
> 85 
Observed number 
of interval cancers 
20 
27 
26 
29 
24 
16 
19 
14 
6 
0 
Expected number in th 
absence of screening 
21.3 
38.2 
47.6 
52.5 
56.1 
50.0 
44.8 
17.2 
7.0 
2.0 
To explore the relation between age and sensitivity more precisely, the 
interval cancer rates in five-year age groups were compared with the expected 
incidence rates in the absence of screening (Table 5.4). This analysis reveals 
that in the 40-44 age group the observed number of interval cancers (n = 20) 
was almost the same as the expected number of clinically manifest cancers in 
the absence of screening (n = 21.3), implying that hardly any of the sympto-
matic cancers in this age group were picked up by previous screening in the 
Nijmegen biennial screening program. The small differences between the 
observed and expected numbers in the > 75 age groups could be biased 
because of the above discussed assumption concerning the expected incidence 
rate in the absence of screening, which might be underestimated. In the other 
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age groups the numbers of cancers prevented from developing clinical symp-
toms are substantial. 
APPENDIX 
Duration of detectable preclinical phase 
In a separate study the growth rate of primary breast cancer was estimated 
from the increase in the tumor shadow using serial mammograms.3 The 
median tumor volume doubling time (DT) of the primary breast cancers diag-
nosed in women aged 50-70 years was 157 days (95% confidence limits, 
121-204 days). This was longer than the DT found in women younger than 
50 years of age at diagnosis, being 80 days (95% confidence limits, 
44-147 days). Primary breast cancer in women older than 70 years of age at 
diagnosis was found to grow even more slowly at a median value of 188 days 
(95% confidence limits, 120-295). 
On the assumption of exponential growth, the time for a tumor to increase 
from a volume of 65 mm3 (corresponding with a spherical tumor of a diameter 
of 5 mm) to 4189 mm3 (corresponding with a spherical tumor of a diameter of 
20 mm) is given by 
mil** 
^-DT. 
In2 
When the duration of the detectable preclinical phase follows an exponential 
distribution, the mean duration is obtained by dividing the median duration by 
ln2, giving 
, 4189 In 
-median DT 
(ln2)2 
with corresponding 95% confidence interval. 
Sensitivity 
The probability that a new case, i.e. a case not yet detectable at a screening 
examination, surfaces clinically before a certain time t has elapsed after the 
screening examination, is given by 
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ι i-b 
¡Ie№ ¡Xe^dudb 
•Ό -Ό 
where I = (preclinical) incidence rate of the disease, b = start of the 
preclinical phase and — = mean duration of the preclinical phase, 
λ 
assuming an exponential distribution for the duration of the preclinical phase 
and modelling interval cancer incidence as a Poisson process.13·20 
If / is small, the expected number of new breast cancer patients among N 
women followed for a time t after screening can be approximated by 
E(new cases) = NI(t-hl-e~u)) 
A 
The expected incidence in the absence of screening is given by 
E=NIt 
The estimate of the sensitivity of the program based only on the interval 
cancer incidence, as was suggested by Day,13 is 
5 = L·* 
E-E(new cases) 
where О = observed number of interval cancers. 
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ABSTRACT 
The benefits of mammographie screening for breast cancer are not clear 
for women less than 50 years old. 
Our aim was to evaluate the effectiveness of breast cancer screening in 
different age groups. 
A mammographie breast cancer-screening program with a 2-year screen-
ing interval has been under way in Nijmegen, The Netherlands, since 1975. 
After eight rounds, more than 40,000 women have been invited to partici-
pate. All breast cancer cases diagnosed in the invited population, whether 
detected by screening or clinically, have been considered in this study. The 
age groups are younger than 50 years, 50-69 years, and 70 years or older 
at last invitation before diagnosis. Our assessment of the effectiveness of 
screening is based on the proportion of screen-detected cancers among all 
cancers and on the disease stage at diagnosis. 
For women younger than 50, compliance was 75%, and 37% (85/230) of 
the cancers were detected by screening. The age group 50-69 years had a 
compliance of 65% with 48% (288/595) of cancers detected by screening, 
and the group 70 years or older had a 25% compliance with 35% 
(108/305) of cancers detected by screening. The sizes of the cancers 
detected by screening were smaller than those detected clinically for all 
age groups. The age group under 50 showed no substantial difference in 
the proportion of positive axillary lymph node status between 
screening-detected and clinically diagnosed cancers, while among older 
women, the proportion of lymph node involvement was substantially 
higher for clinically detected cases. A significantly lower frequency of 
advanced stages was observed in screen-detected compared with clinically 
diagnosed cancers for women 50 years of age or older (P < .001) but not 
in women under 50 (P = .35). 
No positive effect of the biennial screening program is apparent for 
women under age 50. For women aged 50 and above, the screen-detected 
cancers have a more favorable stage distribution than clinically diagnosed 
cancers, a prerequisite for a reduction in breast cancer mortality. 
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INTRODUCTION 
Since the 1960s, several screening programs for breast cancer detection have 
been carried out in North America and Western Europe. For women 
aged 50-69 years, the results in general consistently show benefits of mammo-
graphie screening for breast cancer, such as a better stage distribution at 
diagnosis and a subsequent reduction in breast cancer mortality.1"5 In women 
younger than 50 years, however, the benefits of screening are not as clear. So 
far, none of the trials5"7 have been able to show convincing evidence of a 
benefit for women in this age group. 
These discouraging results might be explained by a follow-up that is too 
short. They may also be explained by other factors, such as frequency of 
screening, sensitivity of the mammographie screening test, less aggressive 
treatment offered to women with mammographically detected breast cancers, 
and the biological nature of the tumor.8 
Although breast cancer mortality is the ultimate evaluation measure, early 
measures may be applied to determine the potential effectiveness of a screen-
ing program, inasmuch as the effect on mortality can only be assessed long 
after the start of the screening program. 
An important initial measure of the effectiveness of the screening program is 
the proportion of cancers detected by screening among the total number of 
cancers, which is partly influenced by the compliance rate. Another initial 
measure of the screening program's effectiveness is the disease stage at diag-
nosis. Patients with cancers detected by screening are expected to benefit from 
the screening program in that they will present with an earlier disease stage, a 
prerequisite for any reduction in breast cancer mortality.9 
In this study, these two early indicators of effectiveness of screening (i.e., 
the proportion of cancers detected at screening among the total number of 
cancers and the stage distribution of the cancers) were evaluated in an ongoing 
program in women of three age groups. These groups consisted of women 
younger than 50 years, 50-69 years old, or 70 years old or older at last invita-
tion to participate in the screening program before breast cancer diagnosis. 
The present analysis is based on the results of eight rounds of biennial 
screening in Nijmegen, The Netherlands. It comprises all cancers detected or 
diagnosed in the period from 1975 to 1992. 
62 
STUDY POPULATION AND METHODS 
In the city of Nijmegen (150,000 inhabitants), a population-based biennial 
screening program for breast cancer was set up in 1975.10 Women were 
invited to participate in the program by birth cohort. In the first screening 
round, all women aged 35-64 years at January 1, 1975 (n = 23,000), were 
invited to participate. In the subsequent screening rounds, older women 
(n = 7,700) were also invited. Since round 5, additional women who had 
reached the age of 40 were invited to participate. 
Single-view mammography was carried out as the only screening modality 
every 2 years. In rounds 1-3, a single lateral view of each breast was taken. 
From round 4 onward, a mediolateral-oblique view was taken instead of a 
single lateral view. By the end of 1990, eight screening rounds had been 
carried out; round 9 started in 1991. 
The present study includes all breast cancer cases that were diagnosed in the 
invited population, before they received the invitation to participate in 
round 9, among both participants and nonparticipants. Patients with lobular 
carcinomas in situ were not included, because they are not treated as breast 
cancer patients. The effect of screening was assessed in the whole target 
population, not just in those who participated in the screening. Since 1975, 
data on all Nijmegen patients with a primary breast cancer have been carefully 
recorded by the local cancer registry of the Department of Pathology and the 
Department of Diagnostic Radiology of University Hospital, University of 
Nijmegen. This data file has been merged with the regional cancer registry of 
the Comprehensive Cancer Center East (Integraal Kankercentrum Oost, 
Nijmegen) and the National Computerized Archive of Pathology Reports 
(Landelijk Geautomatiseerd Pathologisch Anatomisch Archief, Amsterdam, 
The Netherlands). 
Among the program participants, cancers either could be detected at screen-
ing (n = 481) or could be diagnosed in the interval between a screening 
examination that gave negative results and the subsequent scheduled screening, 
the so-called "interval cancers" (n = 280). A cancer was classified as a "non-
participant cancer" if it was diagnosed in a woman after she had received an 
invitation to participate in the screening and had chosen not to and before she 
had received an invitation to the next screening (n = 369). 
We considered two early indicators of screening effectiveness on future 
breast cancer mortality. The first indicator was the proportion of cancers 
detected at screening. We distinguished between detection at screening after 
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the first invitation and after a later invitation. The relatively high detection rate 
at first invitation would not be representative of the ongoing screening situ­
ation. 
The second indicator was the stage distribution of the cancers. Tumor size 
and axillary lymph node involvement of screen-detected and clinically diag­
nosed cancers were compared among women who were in one of the follow­
ing age groups at last invitation before diagnosis: younger than 50 years, 
50-69 years, and 70 years or older. 
Only the sizes of invasive lesions were included. The largest diameter of the 
tumor mass was assessed mammographically in 90% of the cases. If this 
diameter could not be assessed mammographically because the margins of the 
tumor were unclear or because the tumor was radiographically occult, the 
diameter was established on the basis of findings from the histologic slides and 
the specimen radiograph. 
In the early years of the screening program, the axillary lymph nodes were 
not routinely examined histologically, but the results regarding lymph node 
status were presented from round 4 onward. In 17 patients with clinically 
diagnosed cancers, all but two among women aged 50 years or older, no 
lymph node dissection was performed because the tumor was at an advanced 
stage and was inoperable. These cases have been recorded as node positive. 
The benefits of screening will come mainly from the improvements in 
prognosis seen in screen-detected cancers. Because of length-time-biased 
sampling, the aggressiveness of cancers detected at a first screening is 
expected to be different from that seen at later screenings. Breast cancers 
detected at a screening examination subsequent to a previous screening exam­
ination that showed negative results give a better indication of any screening 
effect. That is why a distinction was made between breast cancers detected at 
a first screening and those detected at successive screenings. A cancer detected 
at screening in a woman who did not participate in the previous round was 
classified as "detected at first attendance". 
To determine the statistical significance of differences in proportions and of 
interactions, statistical analyses of contingency tables were performed.11 A 
two-sided significance level of .05 was used. The statistical tests used were 
based on likelihood ratio statistics. In the case of two-dimensional contingency 
tables, these tests were similar to the familiar Pearson chi-square tests. Differ­
ences in the relationships among the different age groups were also tested with 
likelihood ratio statistics as described in.11 
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RESULTS 
After eight rounds, more than 40,000 women have been invited to participate. 
A total of 18,000 women received their first invitation to participate in the 
screening while they were younger than 50 years of age, 15,000 women were 
between 50 and 69 years of age at first invitation, and 7,000 women were 70 
years of age or older. In round 8 (1989-1990), 5,500 of the invited women 
were still younger than 50 years of age, 15,000 were between 50 and 69 years 
of age, and 8,800 were 70 years old or older. The attendance rate stabilized at 
approximately 70% for women younger than 50 years of age and at about 
60% for women aged 50-69 years, while in the group of women aged 
70 years or older, less than 25% of the invited women participated in the 
latest rounds (rounds 4-8). 
The proportion of cancers detected at screening, including in situ and inva-
sive cancers, differed significantly between the age groups (P < .001). 
Table 6.1 shows that only 37% of the breast cancers diagnosed in women 
under 50 years of age were detected at screening, 38% of the cancers were 
classified as interval cancers, and 25% were classified as nonparticipant can-
cers. In the 50- to 69-year-old age group, 48% of the cancers were detected at 
screening, 26% were classified as interval cancers, and 26% were classified as 
nonparticipant cancers (Table 6.1). Despite the low attendance rate in the 
oldest age group (> 70 years), 35% of the cancers were detected at screen-
ing, and the majority (52%) of the cancers in this age group were classified as 
nonparticipant cancers (Table 6.1). For all age groups, no improvement in the 
proportion of screen-detected cancers was seen when we compared the results 
obtained in the first few rounds with those obtained in the more recent rounds. 
Table 6.2 shows the size of the invasive cancers by method of detection 
(i.e., screening or clinical diagnosis between two successive scheduled screen-
ing visits or among women who declined to participate) in three groups 
formed according to age at the last invitation to participate before diagnosis. 
The tumors observed in screen-detected cancers were significantly smaller than 
those observed in clinically diagnosed cancers. This difference was more 
pronounced in women 50 years of age or older (P = .06). In the group 
younger than 50 years, nearly 20% of the cancers detected at a successive 
screening examination had a diameter of 10 mm or less, while the percentage 
of such cancers was twice as high in the age group 50 or older. The propor-
tion of clinically diagnosed cancers of 10 mm or less was about 10%, irre-
spective of age group. A small, but not statistically significant, decrease in the 
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TABLE 6.1 Number of women screened at first or successive invitations and 
number of breast cancers detected at screening or clinically diag-
nosed among participants and nonparticipants in the subsequent 
periods between screening invitations 
Screening rounds 1-8 
First invitation 
No. of women screened 
Attendance rate 
Cancer at screening 
Interval cancer' 
Nonparticipant cancer' 
Total 
Successive invitations 
No. of women screened 
Attendance rate 
Cancer at screening 
Interval cancer' 
Nonparticipant cancer1 
Total 
Total invitations 
No. of women screened 
Attendance rate 
Cancer at screening 
Interval cancer* 
Nonparticipant cancer' 
Total 
Age at 
< 50 
14852 
81% 
29 (50%) 
25 (43%) 
4(7%) 
58 
32617 
72% 
56 (33%) 
63 (37%) 
53(31%) 
172 
47469 
75% 
85 (37%) 
88 (38%) 
57 (25%) 
230 
screening invitation, y 
50-69 
11842 
78% 
67 (66%) 
18(18%) 
17 (17%) 
102 
62845 
63% 
221 (45%) 
136 (28%) 
136 (28%) 
493 
74687 
65% 
288 (48%) 
154 (26%) 
153 (26%) 
595 
> 70 
2460 
34% 
28 (54%) 
6 (12%) 
18 (35%) 
52 
10883 
24% 
80 (32%) 
32 (13%) 
141 (56%) 
253 
13343 
25% 
108 (35%) 
38 (12%) 
159 (52%) 
305 
Cancer diagnosed in the interval between a screening examination that 
gave negative results and the subsequent scheduled screening. 
* Cancer diagnosed in a woman after she had received an invitation to 
participate in the screening and had chosen not to and before she had 
received an invitation to the next screening. 
TABLE 6.2 Invasive breast cancer cases by tumor size from screening 
rounds 1 to 8 
Age at last screening invitation 
before diagnosis, y* 
Breast cancer" 
Screen-detected 
First attendance* 
Invasive tumor size, mm 
< 10 
11-20 
> 20 
Total 
DCIS 
Successive attendances 
Invasive tumor size, mm 
< 10 
11-20 
> 20 
Total» 
DCIS 
Clinically diagnosed 
Interval cancer " 
Invasive tumor size, mm 
< 10 
11-20 
> 20 
Total» 
DCIS 
Nonparticipant cancer1 
Invasive tumor size, mm 
< 10 
11-20 
> 20 
Total» 
DCIS 
< 50 
5(19) 
19 (70) 
3(11) 
27 
10 (27) 
6(19) 
19 (61) 
6(19) 
31 
17 (35) 
11 (14) 
36(44) 
34 (42) 
81' 
6 (7) 
4 (8) 
24 (46) 
24 (46) 
522 
3 (5) 
50-69 > 70 
27 (29) 
49 (52) 
18 (19) 
94 
6 (6) 
64(42) 
71 (46) 
19 (12) 
154' 
33 (18) 
8 
24 
15 
47 
7 
20 
23 
5 
48 
6 
(17) 
(51) 
(32) 
(13) 
(42) 
(48) 
(10) 
(11) 
16(11) 
68 (47) 
61 (42) 
145' 
8 (5) 
15 (10) 
38 (26) 
93 (64) 
1462 
5 (3) 
7 
19 
9 
35' 
2 
7 
39 
98 
1441( 
5 
(20) 
(54) 
(26) 
(5) 
(5) 
(27) 
(68) 
) 
(3) 
' DCIS = ductal carcinoma in situ. 
I
 Values in columns = number of cases (%). 
* Includes screen-detected patients who did not participate in the previous 
round of screening. 
8
 Superscript numbers indicate the number of invasive cancers of unknown 
sizes. 
II
 Cancer diagnosed in the interval between a screening examination that gave 
negative results and the subsequent scheduled screening. 
1
 Cancer diagnosed in a woman after she had received an invitation to partici-
pate in the screening and had chosen not to and before she had received an 
invitation to the next screening. 
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TABLE 6.3 Breast cancer cases by axillary lymph node status from screening 
rounds 4 to 8 
Breast cancer 
Screen-detected 
First attendance* 
Negative node* 
Positive node 
Total* 
Successive attendances 
Negative nodet 
Positive node 
Total* 
Clinically diagnosed 
Interval cancer5 
Negative node* 
Positive node 
Total* 
Nonparticipant cancerB 
Negative node* 
Positive node 
Total* 
Age at last screening invitation 
before diagnosis, y 
< 50 
8 
5 (38%) 
13 
19 
12 (39%) 
31 
26 
28 (52%) 
54 
22 
16 (42%) 
382 
50-69 
18 
9 (33%) 
27' 
101 
28 (22%) 
129 
63 
30 (32%) 
933 
51 
57 (53%) 
108' 
> 70 
18 
6 (25%) 
242 
34 
9 (21%) 
434 
18 
8 (31%) 
265 
40 
50 (56%) 
90" 
Includes screen-detected patients who did not participate in the previous round. 
* Ductal carcinoma in situ cases have been included as negative. 
* Superscript indicates the number of cancers with unknown axillary node status. 
i
 Cancer diagnosed in the interval between a screening examination that gave 
negative results and the subsequent scheduled screening. 
11
 Cancer diagnosed in a woman after she had received an invitation to participate 
in the screening and had chosen not to and before she had received an invita-
tion to the next screening. 
size of screen-detected cancers was seen in the group under age 50 during the 
period that mediolateral-oblique views were taken compared with the earlier 
time period when a single lateral view was taken. 
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TABLE 6.4 Invasive breast cancer cases by stage from screening rounds 4 
to 8 
Breast cancer 
Screen-detected 
First attendance* 
Stage I 
Stage 11+ 
Total* 
Successive attendances 
Stage I 
Stage 11 + 
Total* 
Clinically diagnosed 
Interval cancer* 
Stage I 
Stage 11 + 
Total* 
Nonparticipant cancer' 
Stage I 
Stage 11 + 
Total* 
Age 
< 50 
3 
5 (63%) 
8 
4 
13 (76%) 
17 
17 
34 (67%) 
51 
13 
22 (63%) 
352 
at last screening invitation 
before diagnosis, y 
50-69 
14 
12 (46%) 
26' 
74 
32 (30%) 
106 
39 
49 (56%) 
883 
24 
81 (77%) 
105 
> 70 
11 
9 (45%) 
20' 
26 
13 (33%) 
393 
12 
12 (50%) 
245 
14 
82 (85%) 
9622 
Includes screen-detected patients who did not participate in the previous round. 
* Superscript numbers indicate the number of invasive cancers with unknown 
stage. 
* Cancer diagnosed in the interval between a screening examination that gave 
negative results and the subsequent scheduled screening. 
' Cancer diagnosed in a woman after she had received an invitation to participate 
in the screening and had chosen not to and before she had received an invitation 
to the next screening. 
The number of ductal carcinomas in situ is also shown in Table 6.2. The 
number detected at screening in younger women was significantly greater than 
that detected at screening in older women (P < .01). 
Table 6.3 shows the axillary lymph node status of screen-detected and 
clinically diagnosed cancers from round 4 onward. There was a marked differ-
Chapter 6 - Early indicators 69 
enee between the age groups. In women 50 years of age or older, about one 
fifth of the cases detected at a successive screening showed axillary lymph 
node involvement, which was significantly lower than in clinically diagnosed 
cancers (P < .001). In the group younger than 50, nearly 40% of the cases 
detected at a successive screening showed axillary lymph node involvement, 
which was not significantly different from that found in clinically diagnosed 
cancers (P = .38). 
The size of the tumor and lymph node status were combined to define stage 
of disease.9 Stage I cancer was defined as a tumor with a diameter of 20 mm 
or less and showing no involvement of the lymph nodes. When the lymph 
nodes were involved or when the tumor diameter was larger than 20 mm, the 
cancer was classified as stage II+. Table 6.4 shows the stage distribution of 
invasive cancers. A significantly lower frequency of advanced stages was 
observed in screen-detected compared with clinically diagnosed cancers in 
women 50 years of age or older (P < .001) but not in women in the younger 
age group (P = .35). 
For all age categories, the biopsy rates were highest in the initial screening 
round and decreased during the program (toward round 8). For the group 
under age 50, rates declined from 7.3 per 1,000 women screened to 4.1; for 
those aged 50-69 years, from 11.1 to 3.3; and for those 70 years old or older, 
from 13.2 to 7.3. 
DISCUSSION 
Women with screen-detected cancers are expected to benefit from a screening 
program. Accordingly, a first indicator of the potential benefit associated with 
screening is the proportion of screen-detected cancers. In our study, in women 
younger than 50 years of age, 37% of the cancers were screen detected; in 
women 50-69 years old, 48% were screen detected; and in women 70 years of 
age or older, 35% were screen detected. In other studies,1-2·412 the percentages 
of cancers detected at screening were considerably higher: between 60% and 
70%. These higher percentages can be partly explained by a higher attendance 
rate of 80% or more4·12 or a more frequent screening schedule.1·2 The percen-
tage of screen-detected cancers in the oldest age group in our study was rela-
tively high (35%), considering the low participation rate (overall, 25%) in this 
age group. This result might be explained by self-selection of women with an 
elevated risk for breast cancer, such as familial history. Another explanation 
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may be that a portion of these cancers would never have been detected during 
the patient's life if no screening had been carried out (overdiagnosis). 
A prerequisite for a reduction in breast cancer mortality is a more favorable 
stage distribution in screen-detected cancers compared with clinically diag-
nosed cancers. This condition was fulfilled in all age groups with regard to 
tumor size at presentation. Although mammographically detected cancers were 
smaller than those detected by palpation, this difference was less apparent for 
younger women than for older women. The proportion of small tumors among 
the screen-detected cancers in the age group 50-69 years old in our study was 
comparable to that of other studies.*·13·14 
Fewer cases with axillary lymph node metastases were observed among the 
cancers detected at successive screenings compared with clinically diagnosed 
cases in women aged 50 years or more but not in those under age 50. About 
20% of the screen-detected cancers in the group of women 50-69 years old 
showed axillary lymph node metastases in our study; this percentage is com-
parable to that reported in other studies.413·14 
Approximately one third of the screen-detected invasive cancers in the 
women 50 years of age or older were advanced (stage II+), which is still 
acceptable according to minimum criteria for screening performance.9 How-
ever, in the group of women younger than 50, as many as two thirds had 
cancers in an advanced stage at diagnosis. Detailed information on the disease 
stage at diagnosis for the group younger than age 50 has been published for 
only two screening projects.7·14 Our results are consistent with the results of 
those studies. The results of the only randomized trial published so far,7 in 
part specifically designed for women aged 40-49 years, showed no reduction 
in the cumulative occurrence of large or lymph node-positive tumors in the 
study group compared with the control group. 
The benefit of mammographie screening seems to differ in young and older 
women. The reduction in size observed in screen-detected cancers compared 
with clinically diagnosed cancers was accompanied by fewer cancers with 
axillary lymph node metastases only in the women 50 years old or older. 
Cross-classification of tumor size and lymph node status (not tabulated here) 
showed that 40% of younger women with very small invasive lesions 
(^ 10mm) had positive nodes - a considerable percentage. In women 50 
years of age or older, the percentage was 20%. Advancing the time of diag-
nosis does not seem to alter the propensity for axillary lymph node invasion in 
women younger than 50 years of age. A different tumor biology in older and 
younger women might explain this finding. If in younger women breast can-
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cers behave as an early systemic disease, i.e., they disseminate early in their 
evolution before they are detectable by current screening methods, advancing 
the time of diagnosis will have little effect on the development of metastasis.15 
In older women, breast cancer may behave as a progressive disease, which 
renders the time of diagnosis more relevant to the question of whether or not 
metastasis has already occurred.16 
The as yet unanswered question regarding ductal carcinoma in situ is the 
likelihood of its progression to invasive cancer. Ductal carcinomas in situ are 
detected more frequently at screening of younger women. If progressive, this 
process may take many years, and a long delay is to be expected before the 
benefit of mammography, in terms of a reduction in breast cancer mortality, 
becomes apparent. 
Our data substantiate the hypothesis that it is more difficult to detect inva­
sive breast cancer in its premetastatic stage in younger women than in older 
women. 
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ABSTRACT 
The use of mammography in recent years has resulted in an increase in 
the detection of small breast cancers. The beneficial effects of early detec-
tion on breast cancer mortality seem to differ with age. To obtain more 
insight into this matter we studied the long-term prognosis of patients with 
early invasive breast cancers (T,) in three age groups: 144 patients of 
age 40-49, 402 patients of age 50-69 and 192 patients 70 years or older at 
diagnosis. 
In all age groups, patients with a tumour of 1 cm or less have a longer 
breast cancer-specific survival than patients with a tumour larger than 
2 cm. The survival advantage in the case of tumours of a size rounded to 
1.5 cm compared with tumours larger than 2 cm in the under age 50 
group was marginal (and not significant). However, older patients with 
tumours of this size do have a significantly improved survival. 
It is more difficult to improve survival in younger patients through early 
detection, partly because of an apparent early metastatic potential of their 
tumours. A reduction in breast cancer mortality might be expected in 
women younger than 50 years of age only if a substantial proportion of 
the invasive cancers are detected before their size exceeds 1 cm. 
INTRODUCTION 
In recent years an increase in the diagnosis of early stage and small breast 
cancers has been reported.1·2 This will be mainly due to the substantial 
increase in the use of mammography for screening purposes or case finding. 
Randomised trials have shown that advanced detection by mammographie 
screening in women 50 years of age or older can result in a reduction of 
breast cancer mortality.3·4 The benefit of mammographie screening in younger 
women is not clear.3 This may be owing to factors relating to the screening 
process itself, such as the sensitivity of the mammographie screening test and 
the frequency of screening. However, an explanation may also be found in the 
biology of the tumour. To provide insight into the nature of breast cancer, 
survival curves by age group and stage of the tumour are compared.5·6 A clear 
trend of increased survival with decreasing size is demonstrated in all age 
groups. However, small tumours detected by screening mammography may 
have a lower malignant potential than small cancers detected by the woman 
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herself.7·8 The malignant potential of breast cancers varies considerably 
between tumours, one factor being differences in growth rate.9 Slow-growing 
tumours have a longer mammographically detectable preclinical phase. There-
fore the likelihood of being detected at screening is greater for slow-growing 
than for faster growing tumours ('length-time bias'). Consequently, a small 
invasive tumour detected by screening might have a better prognosis than a 
clinically diagnosed cancer of the same size. To study the prognosis of small 
breast cancers, it is therefore important to take account of the mode of detec-
tion, i.e. clinically diagnosed vs screen-detected. 
Since 1975 in Nijmegen a biennial mammographie screening programme has 
been conducted for women over age 35 at the start of the project.10 The 
follow-up of breast cancer patients, either clinically diagnosed or detected at a 
screening examination, provides an opportunity to study the breast cancer 
specific survival of the patients over an 18 year period, in particular the sur-
vival of those with invasive tumours 2 cm or less in size (T,). 
PATIENTS AND METHODS 
Since 1975, data on all Nijmegen patients diagnosed as having breast cancer in 
either one of the two Nijmegen hospitals have been carefully recorded by the 
local cancer registry of the Departments of Diagnostic Radiology and Pathol-
ogy of the Nijmegen University Hospital and of the Canisius Wilhelmina 
Hospital. On record at the end of 1992 were 1333 patients, 40 years of age or 
older, diagnosed with primary breast cancer. Patients with lobular carcinomas 
in situ were not included because they are not treated as breast cancer patients. 
Cancers were detected either in the screened population at a screening exami-
nation (n = 538) or in the interval between the scheduled examinations, or 
among nonparticipants of the programme or before the first screening invita-
tion. 
Tumour size of invasive lesions was determined mammographically. If the 
diameter could not be assessed mammographically, the histologically deter-
mined diameter was substituted (in 10% of the measurements). Tumour size 
was available in all but 19 of the invasive cases. There was a clear tendency to 
round measurements to the nearest 0.5 cm. Therefore we used the following 
categories of tumour size: 1 cm or less, 1.5 cm, 2 cm, 2.5-4.5 cm, 5 cm or 
larger. 
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The vital status of the Nijmegen breast cancer patients was acquired from 
the local registrar's office. At the end of 1993, 478 of the 1333 patients had 
died. All clinical information on these patients was gathered to classify the 
cause of death, i.e. either breast cancer or another cause. Breast cancer was 
considered to be the underlying cause of death when distant metastases had 
been reported before death and competing causes of death could be ruled out. 
For ten patients the cause of death could not be assessed. Five of them were 
diagnosed with early invasive breast cancer, i.e. involving a tumour 2 cm or 
less in diameter. 
Breast cancer specific survival curves obtained with the life-table method," 
were calculated for patients diagnosed with in situ ductal cancers and invasive 
tumours by size groups and for three age groups: 40-49, 50-69, > 70 years of 
age at diagnosis. Deaths from causes other than breast cancer were treated as 
censored observations in the survival analysis. The survival advantage with 
decreasing size was expressed as the ratio of the hazards of dying from breast 
cancer. Adjustment for the detection mode, i.e. screen-detected or clinically 
diagnosed, was accomplished with a proportional hazards regression analysis, 
applied by age group." 
RESULTS 
Among the 260 younger patients, being 40-49 years at diagnosis, 144 patients 
were diagnosed with a small (2 cm or less) invasive breast tumour. Of the 
672 patients in the 50-69 age group, 402 patients had a small invasive tumour 
and in the older age group (> 70 years) 401 patients were diagnosed, of 
whom 192 had a small invasive tumour. 
The breast cancer survival curves by size of the tumour for each of the 
three age groups are displayed in Figures 7.1 to 7.3. The 5-, 10- and 15 year 
breast cancer specific survival rates for younger patients (40-49 years) diag-
nosed with a small invasive tumour of 2 cm or less were 88%, 75% and 66% 
respectively. The corresponding survival percentages for patients in the 50-69 
age group were 92%, 78% and 73% respectively. In the oldest age group 
(> 70 years) 90% and 83% of the patients did not die from breast cancer 
within 5 and 10 years respectively, after diagnosis. The number of older 
patients at risk of dying from breast after 15 years of follow-up was too small 
to calculate the 15 year breast cancer specific survival for the > 70 age 
group. 
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ο.β 
Years a f t e r diagnosis 
+ DCIS (0/37) 
* < Um (5/39) 
Π 1.5 cm (8/49) 
О 2 cm (15/56) 
О 2.5^.5 cm (17/58) 
Δ а 5 cm (9/17) 
FIGURE 7.1 Breast cancer survival for patients 40-49 years of age at diag­
nosis with DCIS and invasive breast cancer by tumour size. 
Between parentheses: number of breast cancer deaths I number 
of breast cancer patients 
1 . 0 
0 . 4 
0 . 0 
Years a f t e r diagnosis 
+ DCIS (1/65) 
+ < 1 cm (17/155) 
D 1.5 cm (18/130) 
О 2 cm (33/115) 
О 2.5-4.5 cm (47/148) 
Δ > 5 cm (25/52) 
FIGURE 7.2 Breast cancer survival for patients 50-69 years of age at diag­
nosis with DCIS and invasive breast cancer by tumour size. 
Between parentheses: number of breast cancer deaths I number 
of breast cancer patients 
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IO 
Years a f t e r diagnosis 
+ DCIS (0/22) О 2 cm (10/74) 
* < lem (3/56) О 2.5-*.5 cm (28/31) 
D 1 5 cm (8/59) Δ > 5 cm (20/40) 
FIGURE 7.3 Breast cancer survival for patients > 70 years of age at diag­
nosis with DCIS and invasive breast cancer by tumour size. 
Between parentheses: number of breast cancer deaths I number 
of breast cancer patients 
Table 7.1 shows the relative hazards of death from breast cancer for patients 
with small invasive cancers (< 2 cm), relative to the hazard of the 2.5-4.5 cm 
size group for the different age categories. Only in the oldest age group 
( > 70 years) is there an indication that patients with tumours of a size 
rounded to 2 cm have a better prognosis than patients with tumours 
2.5-4.5 cm in size. The survival advantage for patients with tumours of a size 
rounded to 1.5 cm (compared with tumours of 2.5-4.5 cm) in the under age 50 
group was marginal (and not significant). However, patients with tumours of 
this size in the above 50 age groups have a significantly improved survival. In 
all age groups patients with tumours of 1 cm or less have a better survival 
than patients with tumours larger than 2 cm. 
Part of the survival advantage of the patients with small invasive tumours 
might be explained by a more favourable biology of the screen-detected small 
tumours ('length time bias'). In younger women 35% (50/144) of the small 
invasive tumours (< 2 cm) were detected at a screening examination. In the 
50- to 69-year-old age group this percentage was 59% (238/402) and in the 
oldest age group 46% (89/192). To adjust for the possible confounding effect 
of detection mode, a proportional hazards model was employed that incor-
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porates size and the mode of detection, that is, screen-detected or clinically 
diagnosed (Table 7.2). The results show that the survival advantages for 
patients with tumours of 2 cm or less (compared with larger tumours) decrease 
only marginally. 
TABLE 7.1 Hazard ratio of dying from breast cancer for patients diagnosed 
with early invasive breast cancer (< 2 cm) with reference to 
patients in the same age group with larger invasive tumours 
(2.5-4.5 cm); 95% confidence intervals are given in parentheses 
Tumour size 
< 1 cm 
1.5 
2 
(cm) 
40-49 
0.37 
(0.14- 1.00) 
0.56 
(0.24- 1.31) 
0.81 
(0.40- 1.61) 
Age at diagnosis (years) 
50-69 
0.26 
(0.15-0.45) 
0.35 
(0.20 - 0.61) 
0.88 
(0.57- 1.38) 
> 70 
0.17 
(0.05 - 0.55) 
0.44 
(0.20 - 0.98) 
0.51 
(0.24- 1.05) 
TABLE 7.2 Hazard ratio of dying from breast cancer for patients diagnosed 
with early invasive breast cancer (< 2 cm) with reference to 
patients in the same age group with larger invasive tumours 
(2.5-4.5 cm), adjusted for detection mode (screen-detected or 
clinically diagnosed); 95% confidence intervals are given in 
parentheses 
Tumour size 
< 1 cm 
1.5 
2 
(cm) 
40-49 
0.38 
(0.14- 1.02) 
0.58 
(0.25- 1.35) 
0.82 
(0.41 - 1.64) 
Age at diagnosis (years) 
50-69 
0.31 
(0.17-0.56) 
0.40 
(0.23 - 0.69) 
0.94 
(0.60 - 1.48) 
> 70 
0.21 
(0.06 - 0.71) 
• 0.53 
(0 .23- 1.21) 
0.56 
(0.27- 1.17) 
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DISCUSSION 
The purpose of mammographie screening is to detect cancers early in their 
development. However, a lower malignant potential of screen-detected cancers 
may limit the effectiveness of screening in saving lives. Few data are currently 
available on the prognosis of patients with small breast cancers, particularly of 
those detected at screening. 
In our study we confirmed, age specifically, the good prognosis of patients 
with cancers 1 cm or smaller, as was demonstrated in other studies.5·6,1213 In 
the youngest age group only 13% of patients with a tumour diameter of 1 cm 
or less died of breast cancer within 10 years. Similarly, in the older age 
groups these failure rates were only 14% and 6% respectively. 
On the other hand, the survival advantage for patients with early breast 
cancers larger than 1 cm differs with age. In the 40-49 age group no signifi-
cant better breast cancer-specific survival could be demonstrated for patients 
with a tumour 1.5 or 2 cm in diameter compared with that of patients with a 
larger tumour of 2.5-4.5 cm. In this age group a substantially better survival 
is gained only in cases where the tumour is 1 cm or less. For women in the 
age group 50-69 at diagnosis the break for a better survival is at 1.5 cm 
tumour size, rising to 2 cm for the > 70 age group, compared with the sur-
vival of patients having larger tumours. Thus it seems to be more difficult to 
improve survival in younger patients. A similar conclusion was reached on the 
basis of the survival results in the Breast Cancer Detection Demonstration 
Project (BCDDP).6 In the BCDDP this finding was explained by a higher 
breast cancer survival rate of younger women with a larger tumour compared 
with that of older women having a tumour of the same size. 
This differential effect of age on breast cancer-specific survival of patients 
with small tumours could explain why it is more difficult to achieve a benefi-
cial effect on breast cancer mortality in women aged 40-49 by mammographie 
screening. While on the one hand to gain survival advantage in this age group 
tumours have to be detected when they are very small, on the other hand it is 
more difficult to spot small malignant tumours in these patients, probably 
because of their frequently observed dense breast tissue.14 
In our study, cancers of a diameter of 1.5 cm or less diagnosed in younger 
women have a greater potential for fatality than tumours of the same size in 
older women. This may be partly explained by an earlier metastatic spread 
indicated by more frequent axillary lymph node involvement. Since 1981, the 
axillary lymph nodes have been routinely examined histologically in the two 
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Nijmegen hospitals. Cross-classification of tumour size and lymph node status 
for the calender period 1981-92 (see Table 7.3) shows that younger patients 
with a tumour of 1.5 cm or less more frequently had lymph node metastasis 
than older patients with a tumour of the same size. Even after adjustment for 
nodal involvement in a proportional hazards model, there is still an indication 
that younger patients with a 1.5 cm or smaller tumour are at greater risk of 
dying from breast cancer than women in the age groups 50-69 and > 70 
(hazard ratio 2.7 (P = 0.07) and 7.6 (P = 0.06) respectively). One explana-
tion may be that nodal involvement in older patients is biologically less impor-
tant regarding risk of distant metastasis compared with node-positive younger 
patients. This is in line with the recently formulated theory of Hellman.15 
TABLE 7.3 Axillary lymph node involvement by age and size (invasive tu-
mours only) 
Age at diagnosis (years) 
40-49 50-69 > 70 
Tumour size (cm) 
42% (n = 
62% (n = 
45% (n = 
64% (n = 
91% (n = 
: 26) 
: 39) 
38) 
•• 39) 
: 11) 
15% (n = 100) 
30% (n = 79) 
43% (n = 63) 
54% (n = 99) 
80% (n = 30) 
25% (n 
21% (n 
38% (n 
58% (n 
78% (n 
= 36) 
= 34) 
= 45) 
= 78) 
= 23) 
Our results indicate that a reduction in breast cancer mortality might be 
expected in women younger than 50 years of age only if a substantial propor-
tion of the invasive cancers are detected before their size exceeds 1 cm. How-
ever, this target is not achieved by film-screen mammography.10 The develop-
ment of new technologies, such as digital mammography and magnetic res-
onance imaging, might offer better prospects in this regard. It is also impor-
tant that small invasive tumours rather than ductal carcinomas in situ are 
detected at screening, as the proportion of in situ tumours that progress to a 
life-threatening disease is uncertain. 
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ABSTRACT 
The objective is to determine the efficacy of screening for breast cancer in 
women aged 40 to 49. 
A large number of women will have to be enrolled to ensure adequate 
statistical power. Attention will be restricted to the deaths from breast 
cancer that occur among comparable groups of patients with breast cancer 
rather than to an analysis in which all women entering into the trial are 
considered at risk of dying from breast cancer (population mortality anal-
ysis). As the new trial is likely to be conducted in regions where screening 
has been established for all women from age 50 onward, comparability 
may be reached by including the breast cancers detected at the routine 
screening examination at age 50. 
When comparability of cases can be reached, such a case mortality 
analysis requires 15-30% fewer women to be enrolled than a population 
approach. 
INTRODUCTION 
In the past two decades several randomised trials of breast cancer screening in 
the age range 40-70 have been conducted to assess the impact of screening 
with mammography on mortality from breast cancer. A reduction of 20-30% 
was seen after a mean follow up of 10 years. Subgroup analysis showed that 
the reductions were mainly due to the screening of women above age 50. 
Therefore, nationwide screening programmes for the age group 50-70 are now 
being implemented in the United Kingdom, The Netherlands, Finland, Iceland, 
and Sweden, ' and pilot projects have been set up in a number of regions of the 
European Community.2 
In 1993 several international conferences reviewed the effect of screening 
women under age 50.3"6 No unequivocal conclusion about screening the 
younger women could be drawn. Inadequate statistical power is one of the 
issues.7 A meta-analysis, however, is difficult to conduct because of differ-
ences in study design, screening intervals, and the screening test used. To 
resolve the issue of screening efficacy in women aged 40 to 49 it has been 
proposed to mount a new trial6 in addition to and in collaboration with the 
continuing UK trial. A tremendous number of women would have to be en-
rolled and followed up for a long time in such a trial, an effort even larger 
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than the trial of the poliomyelitis vaccine in the early 1950s, where 400,000 
children were enrolled but followed up for only 15 months.8 
Recently, it has been shown that evaluating the impact of screening in a 
subcohort of women who develop breast cancer is more powerful than the 
"traditional" population mortality approach based on the experience of all 
women randomised to the test and control groups,911 as to reach statistical 
significance fewer women are required. In the former approach, based on case 
mortality, the two groups of patients with cancer selected for analysis must be 
"comparable" groups of patients. As the proposed under age 50 trial will 
probably be conducted in regions where screening programmes from age 50 
onward have already been implemented, comparability of cases may be 
reached by including the cases detected at routine screening at age 50 in both 
groups. 
Sample sizes required for a breast cancer screening trial under age 50, when 
routine screening starts at age 50, will be worked out for the population mor­
tality approach and the case mortality approach. 
METHODS 
Usually, the calculations of sample sizes for screening trials are made for 
screening programmes in which screening is periodically offered to the study 
group throughout the total follow up period, and no screening is offered to the 
control group.1213 In a breast cancer screening trial starting before the age of 
50, the follow up period is likely to go beyond the age of 50, which is the age 
at which both groups will be screened as part of an established screening 
programme. 
The statistical evaluation of screening efficacy can be based on the popula­
tion breast cancer mortality - that is, the number of deaths from breast cancer 
divided by the total population size, or based on the case mortality - that is, 
the number of deaths from breast cancer divided by the number of patients 
with cancer. These two death rates will now be elaborated for the situation 
where routine screening starts at age 50 and the age of enrolment is 40 and 
45 years, respectively. 
The probability of developing breast cancer clinically before the age of 50 
for women being disease free at entry is given by 
50 -age at entry 
j ie~adx - (50-age at entry)i 
о 
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where i = incidence rate of breast cancer for women in their forties. 
The probability of dying from breast cancer, which is diagnosed before the 
age of 50, within Γ years after the proposed age (< 50) of entry (age at 
entry + Τ > 50) for women free from disease at entry can be given by 
50 -age at entry T-x 
ƒ ie'a ƒ ôeizdzdx (1) 
о о 
where δ is the hazard rate of dying from breast cancer, assuming an exponen-
tional survival time distribution.13 
The benefit of screening starting before the age of 50 is not restricted to 
patients in whom breast cancer is clinically diagnosed before the age of 50: 
also patients detected at the routine screening examination at age 50 may 
derive benefit from it. 
At the routine screening examination at age 50 the detection rate of cancers 
will be approximately equal to ¿λ, where λ is the mean duration of 
preclinical disease. The lead time of these cases detected by screening, 
assumed to have an exponential distribution with parameter l/λ, will have to 
elapse before the survival time after clinical diagnosis becomes effective. 
Because these cases found by screening are detected and treated earlier, they 
are likely to have an improved survival after the lead time. Therefore an 
exponential distribution with parameter rô (0 < r <, 1) for the survival after 
the lead time is expected. 
The probability of dying from breast cancer, that is preclinical at age 50, 
within Τ years after the proposed age at entry (age at entry + Τ > 50) is 
given by 
T-(S0-age at entry) l T-(50-age at entry)-i 
ik ƒ -e'1" ƒ rbe-rizdzdx (2) 
о о 
So, the probability of dying from breast cancer which is diagnosed up to and 
including the screening examination at age 50 can be obtained by summation 
of the two probabilities (1) and (2), and the result is called the population 
mortality. Screening starting under age 50 aims at reducing this probability. 
The statistical significance of the reduction will be assessed with a χ2 test. 
The sample size formula for the number of screened subjects associated with a 
reduction from p0 to px is given by
14 
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S (1 • hpq + ^ 
P\a\ 
* * * c) 
where ql = l-pl and q0 = l-p0; с = the ratio of the number of control to 
screened subjects; p= ^ ^ i and q = l -p; and α denotes the significance level 
of the test and 1 - β the desired power for the anticipated reduction. For a one 
sided test ζ is taken to be the value of the standard normal distribution that is 
exceeded with probability α. For a two sided test z0 is taken to be the value 
that is exceeded with probability a/2. z« is taken to be the value of the stan­
dard normal distribution that is exceeded with probability β . 
Determination of sample sizes based on the population mortality gives the 
required number of women who are to participate in the screening pro­
gramme. 
The probability of dying from breast cancer for a woman free from disease 
at the start can be expressed as the product of the probabilities of developing 
breast cancer ((50 -age at entry)i + ki) and of dying from breast cancer given 
that breast cancer has developed (case mortality). The case mortality can thus 
be obtained by dividing the population mortality by (50-age at entry)i + Xi. 
Note that this measure is defined from the time of entry, not from the time of 
diagnosis, and should therefore not be confused with the so-called case fatality 
rate. Determination of sample sizes based on the case mortality applying 
formula (3) gives the required number of patients with breast cancer. To attain 
this number of patients the required number of women who are to participate 
in the screening programme can be calculated. 
Example 
Consider a screening programme starting at age 40 and a follow up period of 
Τ = 12 years. For women in their forties the average incidence of breast 
cancer (i ) is about 0.0015 per woman-year and the five year survival rate 
from breast cancer is about 0.80, giving a hazard rate of δ = -— log0.80 = 
0.045. For cases detected by screening at age 50 the mean lead time (λ) 
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derived from literature will be about two years and the mortality reduction (r) 
due to early treatment is set at 0.5. Applying these figures to formulas (1) and 
(2) gives a population mortality of 0.003986 (p0). Thus when screening is 
started at age 40 and 100,000 women are screened, about 400 women dying 
from breast cancer could potentially benefit within 12 years. A reduction of 
20% reduces this probability to 0.003189 (p,). Corresponding to α = 0.05 
(one sided) and β = 0.20, one has z
a
 =1.64 and zp = 0.84, so that, when 
the control group is chosen to be twice as large as the study group, equation 
(3) results in 52,800 women required to participate in the screening pro­
gramme. 
Dividing the population mortality by the probability of developing breast 
cancer, being 12 x 0.0015 = 0.0180, gives a case mortality of 0.221 (p0). 
This means that, when screening is started at age 40 and 100,000 women are 
screened, 22% of the 1800 expected patients could potentially benefit within 
12 years. A reduction of 20% reduces this probability to 0.177 (p,). Accord­
ing to equation (3), the required number of patients with breast cancer in the 
screened population is 762. This number will be expected to be diagnosed 
when 42,300 women participate in the screening programme. 
RESULTS 
For breast cancer screening in the under age 50 group, two ages of entry are 
commonly considered - namely 40 and 45. Follow up periods of 10, 12, and 
15 years are considered. Table 8.1 shows the population and case mortality for 
various combinations of age at entry and follow up period, assuming constant 
values for the incidence of breast cancer (i = 0.0015 for age at entry of 
40 and i = 0.0018 for age at entry of 45), the hazard rate of dying from 
breast cancer (δ = 0.045), and the mortality reduction for the cases detected 
by screening at age 50 (r =0.5). 
As the trial is designed to demonstrate a possible benefit of screening and 
no one is interested in demonstrating a possible harmful effect of screening, a 
one tailed test ought to be applied (a = 0.05). To reduce the financial costs 
of the trial the control group is chosen to be twice as large as the study group. 
Tables 8.2 to 8.5 summarise the sample sizes required in the screening group 
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to demonstrate with a power of 80% that screening is beneficial when reduc-
tions of 15%, 20%, 25%, and 30%, respectively, are expected. 
These figures illustrate that an analysis based on case mortality 
requires 15-30% fewer women to be enrolled than an analysis based on popu-
lation mortality. 
TABLE 8.1 Probability of breast cancer being diagnosed up to and including 
screening at age 50, probability of dying from breast cancer in 
the population free from disease at the start (population mortali-
ty), and the conditional probability of dying from breast cancer, 
given that breast cancer has developed (case mortality) 
Age at Probability of diagnosis of Follow up Population Case 
entry breast cancer up to and inclu- period mortality mortality 
(years) ding screening at age 50 (years) 
40 0.0180 10 
12 
15 
0.002906 
0.003986 
0.005524 
0.161 
0.221 
0.307 
45 0.0126 10 0.002799 0.222 
12 0.003490 0.277 
15 0.004436 0.352 
DISCUSSION 
A trial for assessing the efficacy of breast cancer screening under age 50 is 
likely to be implemented in regions where screening from age 50 onward is 
routine for all women. To attain a certain power the trial requires a tremen-
dous number of women. An efficient approach, therefore, will be welcome. 
An analysis based on case mortality requires 15-30% fewer women to be 
enrolled. In such analysis the number of patients with breast cancer that might 
benefit from the additional screening under age 50 is used as the denominator, 
whereas in the population mortality analysis all women entered into the trial 
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TABLE 8.2 Sample sizes in study group required to detect a mortality reduc-
tion of 15% with a power of 0.80 using a one sided test with 
a = 0.05. The control group is twice as large as the study group 
Age at entry Follow up Analysis based on: 
(years) period (years) Population mortality Case mortality* 
40 10 
12 
15 
45 10 
12 
15 
132,000 
96,100 
69,300 
137,000 
109,800 
86,300 
112,700 
76,700 
49,600 
109,000 
81,700 
58,200 
(2029) 
(1381) 
(893) 
(1373) 
(1029) 
(733) 
' Within parentheses the required number of patients with breast cancer in the 
study group. 
TABLE 8.3 Sample sizes in study group required to detect a mortality reduc-
tion of 20% with a power of 0.80 using a one sided test with 
a = 0.05. The control group is twice as large as the study group 
Age at entry Follow up Analysis based on: 
(years) pi 
40 
45 
1 (years) 
10 
12 
15 
10 
12 
15 
Population mortality 
72,600 
52,800 
38,000 
75,200 
60,300 
47,400 
Case mortality* 
62,100 
42,300 
27,500 
60,200 
45,200 
32,300 
(1118) 
(762) 
(495) 
(758) 
(569) 
(407) 
Within parentheses the required number of patients with breast cancer 
in the study group. 
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TABLE 8.4 Sample sizes in study group required to detect a mortality reduc-
tion of 25% with a power of 0.80 using a one sided test with 
a = 0.05. The control group is twice as large as the study group 
Age at entry Follow up Analysis based on: 
(years) pi 
40 
45 
1 (years) 
10 
12 
15 
10 
12 
15 
Population mortality 
45,200 
32,900 
23,700 
47,100 
37,600 
29,600 
Case mortality* 
38,900 
26,600 
17,300 
37,800 
28,400 
20,300 
(701) 
(478) 
(311) 
(476) 
(358) 
(256) 
" Within parentheses the required number of patients with breast cancer 
in the study group. 
TABLE 8.5 Sample sizes in study group required to detect a mortality reduc-
tion of 30% with a power of 0.80 using a one sided test with 
a = 0.05. The control group is twice as large as the study group 
Age at entry 
(years) 
40 
45 
ow-up 
I (years) 
10 
12 
15 
10 
12 
15 
Analysis 
Population mortality 
30,600 
22,300 
16,100 
31,800 
25,500 
20,000 
based on: 
Case mortality* 
26,400 
18,100 
11,800 
25,700 
19,400 
13,900 
(476) 
(325) 
(212) 
(324) 
(244) 
(175) 
Within parentheses the required number of patients with breast cancer 
in the study group. 
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are included in the denominator. The numerator - that is, the number of deaths 
from breast cancer, where breast cancer is diagnosed up to and including the 
first routine screening, is the same in both analyses. The main reason for the 
reduction in sample sizes in the case mortality analysis is the smaller binomial 
variance that goes with it. This is illustrated by the formula for the variance, 
which can be expressed as Ε χ (1 - ρ). The expected number of deaths from 
breast cancer, E, is the same in both analyses, but (1 - p), the complement of 
the mortality, is smaller for the case mortality. 
The deaths among the women with breast cancer detected at the screening at 
age 50 have to be included in both analyses. Some of the patients in the study 
group whose breast cancer is detected by screening before age 50 may corre­
spond to patients diagnosed clinically after age 50 in the absence of any screen­
ing. If these patients did in fact benefit from the earlier diagnosis and treat­
ment, excluding the control group counterparts dilutes the screening effect. 
These patients are now also included in the control group because they will be 
detected at the routine screening at age 50. 
The analysis based on case mortality is more powerful than the population 
mortality analysis, but for the former analysis it is essential that the two 
groups of patients with cancer selected for analysis are comparable.11 When 
both arms of the trial will be screened at age 50, comparability is likely to be 
accomplished by including the patients whose breast cancer is detected by the 
screening examination at age 50. Some of the patients in the study group 
whose cancer was detected by screening before age 50 would never progress 
to clinical disease in the absence of screening. These patients are now also 
included in the control group because their cancer will be detected by screen­
ing at age 50. Thus at the first routine screening round in the control group 
the not yet diagnosed counterparts of the study group cancers will be detected 
and the composition of the patient groups will be the same with regard to their 
prognosis in the absence of screening under age 50. Comparability of cases of 
breast cancer will not be obtained, however if regression of breast cancers 
- for example, of ductal carcinoma in situ, takes place within a period of five 
to 10 years. Although it is suggested that not all ductal carcinoma in situ will 
develop into invasive carcinoma when left untreated,16 there are no published 
reports about the possibility of regression of such preinvasive lesions. 
In the Swedish two county study - a randomised trial of breast cancer screen­
ing conducted in women aged 40-74 years at entry - screening was offered to 
the control group after the initial publication of beneficial effects on breast 
cancer mortality. This was after four rounds of screening in women aged 
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40-49. The incidence equalised after the first screening of the control group in 
the study as a whole, but in the 40-49 age group there was still an excess of 
26% in the initially screened group compared with the initial control group.17 
When this excess can be attributed to the detection of non-malignant lesions it 
has no impact on the number of deaths from breast cancer. Misclassification 
of the cause of death in these younger patients is not likely. In the case mor-
tality analysis such an excess should be substracted from the study group 
cancers. 
Generally, cancer incidence increases with age and the breast cancer death 
rate will not be constant. Therefore, our death rates should be modified to 
account for these changing parameters. Nevertheless, under less stringent 
assumptions, like a linear increase of 0.0001 a year in the incidence of breast 
cancer, starting with an annual incidence rate of 0.001 for women of age 40, 
and the relative survival rates as published by Adami,15 the probabilities in 
Table 8.1 change only marginally. 
Non-attendance of screening in the study group will dilute the effect of 
screening. If non-attendance is not related to the risk of developing breast 
cancer or dying from breast cancer, then the non-participants will have about 
the same probability of dying from breast cancer as the control subjects. If the 
reduced risk of dying from breast cancer among the participants is denoted by 
RR, the reduced risk in the total study group is S x ÄÄ + (1-S), where S is 
the compliance rate. An RR of 0.80 and a compliance rate of 0.75 result in a 
risk ratio of 0.85 for the study group compared with the control group. So, 
the sample sizes in Table 8.2 (15% mortality reduction) will suffice to show a 
mortality reduction of 20% among the participants if the response rate is 75%. 
Also, contamination of the control group will dilute the effect of screening. 
When this contamination is such that 10% of the control group have regular 
screening under age 50, the risk ratio will be 0.85 if the response rate in the 
study group is 70% and the mortality reduction among the participants is 25% 
(07о»о75*озо)
 I n m i s situation the sample sizes in Table 8.2 will suffice. 
0 90+0 10x0 75 r 
It is concluded that when comparability of cases can be reached, a case 
mortality approach requires 15-30% fewer women to be enrolled than an 
analysis based on population mortality. Further gain in efficiency might be 
obtained if surrogate end points were used. However, more research is needed 
to identify suitable surrogates. 
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Randomised controlled trials have shown that screening by mammography can 
reduce mortality from breast cancer. There is general consensus that mammo-
graphie screening is effective in women age 50 and older, but considerable 
controversy remains over the utility of screening women aged 40-49. The 
debate has centered on the interpretation of the results among women in their 
forties in the randomised trials. Recognition of the limited statistical power in 
individual randomised controlled trials has led to meta-analyses of the pub-
lished results,1,2 despite differences in study design, e.g., in the age of recruit-
ment being 40 or 45 years, and in the length of the screening interval being 
one or two years. Cumulative data gathered for periods ranging from 7 to 18 
years of follow-up have been combined for meta-analytic purposes. No une-
quivocal conclusions about the beneficial effect of mammographie screening of 
women in the under age 50 group could be drawn, the insufficient length of 
follow-up being considered a major obstacle. It is expected, however, that a 
breast cancer mortality reduction, if any, will be delayed in women aged 
40-49 years due to the better relative survival of younger patients.3 
In the Nijmegen screening project, the long-term breast cancer mortality in 
young women who had the opportunity of receiving mammographie screening 
once every two years could be studied for the entire observation period of 
16 years. Most studies use the difference in cumulative mortality as the 
measure of effect. However, this approach obscures the effect of screening 
because there is a lag of several years between screening and the time that 
deaths would have otherwise occurred and thus mortality during the early 
years of a programme cannot be influenced by screening. In the relevant 
observation period, set to begin one decade after the start of the Nijmegen 
programme, a shift towards a reduction emerges, but unfortunately the data 
are as yet inconclusive because of small numbers.4 Therefore, the longer 
follow-up of the Nijmegen programme does not resolve the issue of long-term 
effectiveness of screening younger women. 
In view of current uncertainty regarding the benefit of mammographie 
screening in younger women, research should focus on factors that can 
enhance the effectiveness of screening younger women. Factors relating to the 
screening process, such as the sensitivity of the mammographie screening test 
and the frequency of screening, may play a contributory role here. Another 
focus of research should be the biology of the tumour. For screening to be 
effective, the diagnosis of a substantial proportion of cancers has to be 
advanced so that treating them will be more effective than if they had been 
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diagnosed clinically. To assess whether increased detection of smaller tumours 
has the same prognostic implications in younger as in older patients, more 
insight into the age-specific relationship between tumour size and prognosis is 
required.5·6 Our study on the prognosis of early invasive breast cancers con-
firmed the results of other studies, indicating that it is more difficult to 
improve survival through early detection in younger patients.7 This may be 
partly explained by earlier metastatic spread of small tumours, indicated by 
more frequent axillary lymph node involvement. Advancing the time of diag-
nosis does not seem to alter the propensity to axillary lymph node involvement 
in women younger than 50 years of age. In women 50 years of age or older, 
however, the smaller size observed in screen-detected as opposed to clinically 
diagnosed cancers was accompanied by fewer cancers with axillary lymph 
node metastases.8 The benefit of mammography may therefore be different in 
younger and older women because of a different natural history of the disease. 
In older women breast cancer may behave as a progressive disease, which 
renders the time of diagnosis more relevant to the question of whether or not 
metastasis has already occurred. If in younger women breast cancers behave 
as an early systemic disease, i.e. they disseminate early in their evolution 
before they are detectable by current screening methods, advancing the time of 
diagnosis will have little effect on the development of metastasis. This could 
be an explanation why it is more difficult to achieve a beneficial effect by 
mammographie screening on breast cancer mortality in women aged 40-49. 
A smaller effect of screening on mortality in women aged 40-49 years is 
likely to emerge considering the relatively low number of cancers detected at a 
screening examination. Because of the faster progress of tumours in younger 
patients,9 cancers become clinically apparent sooner after a negative exami-
nation in younger women than in older women. Patients with these so-called 
interval cancers have received less benefit, if any, from screening, so the 
expected reduction in mortality will be lower for younger women. More 
frequent screening will decrease the proportion of interval cancers and 
increase the proportion of cancers detected by screening. Therefore, the inter-
val between screening rounds should be shortened to achieve a greater benefit 
in this age group. In addition, approximately one third of the screen-detected 
cancers in the Nijmegen project in younger patients are ductal carcinomas in 
situ, compared with only 5% in clinically diagnosed cancers.8 The natural 
history of this pathologic finding is not clear. The proportion of in situ cancers 
that progresses to a life threatening disease is uncertain. Some of them would 
never have been detected during the patient's life if no screening had been 
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carried out. This implies overdiagnosis and overtreatment. If the in situ cancer 
progresses to the invasive stage, this process may take many years and a long 
delay is to be expected before the benefit of mammography in terms of a 
reduction in breast cancer mortality becomes apparent. 
In addition to the growth rate, another factor that results in a relatively high 
number of interval cancers is the lower sensitivity of the mammographie 
screening test in the younger age group. To estimate the numbers of cancers 
missed by the screening test, we limited the number of interval cancers by 
excluding those cases that are expected to have surfaced in the interval period 
because of a high growth rate. Other sensitivity studies do not exclude these 
'fast growing' cancers. With our approach we demonstrated that preclinically 
present cancers in the breasts of younger patients had a higher probability to 
be missed by mammography in the Nijmegen screening project.10 It appears to 
be more difficult to spot small malignant lesions in younger patients, probably 
because of the dense breast tissue more frequently observed in them. Still, 
mammography remains the best technology available for early breast cancer 
detection.11 New technologies, such as digital mammography, magnetic reso-
nance imaging and gene mutation tests, are not ready yet to replace screen-
film mammography. But although more sensitive screening techniques will 
detect smaller breast cancers and more frequent screening will reduce the 
proportion of interval cancers, the question remains whether a reduction in 
breast cancer mortality will eventually emerge. This depends on the above-dis-
cussed natural history of the disease. 
From a scientific point of view, mountening a new randomised trial seems 
to be the best solution to resolve the issue of the efficacy of screening in the 
under age 50 group. Presently, the state of knowledge about specific risk 
factors is insufficient to justify limiting screening efforts to high risk popula-
tions of premenopausal women.11 Because of the low breast cancer mortality 
rate in younger women, a tremendous number of women would have to be 
enrolled and followed up for a long period in such a trial.12 The trial should 
therefore be a combined international effort with strict guidelines for quality 
assurance and specific quality control of mammography and pathology. 
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SUMMARY 
In 1993, the European Society for Mastology (EUSOMA) Breast Cancer 
Screening Evaluation Committee stated that "... The results of randomised 
trials show, without doubt, that breast cancer screening by periodic exami-
nation reduces mortality from breast cancer .... At present there is a sugges-
tion that screening women under age 50 may be less effective than screening 
older women, and may have no effect at all. Data on screening women under 
50 years of age are, however, sparse, and the results therefore still inconclu-
sive" (Wald NJ, Chamberlain J and Hackshaw A. The Breast 1993; 2: 
209-216). The results of the long-term breast cancer screening programme of 
Nijmegen may contribute to resolving the issue of the efficacy of screening 
younger women. 
The population based biennial screening programme for breast cancer in the 
city of Nijmegen, the Netherlands, was set up in 1975. Women were invited 
to participate in the programme by birth cohort. In the first screening round, 
all women aged 35-64 years at January 1, 1975 (n = 23,000) were invited to 
participate. In the subsequent screening rounds, older women (n = 7,700) 
were also invited. Since round 5, additional women who had reached the age 
of 40 were invited to participate. 
The ultimate evaluation measure of the effect of mammographie screening is 
breast cancer mortality. In Nijmegen, after 16 years of follow-up, the cumula-
tive breast cancer mortality among women under age 50 at the start of screen-
ing showed a non-significant reduction of 6% (95% confidence interval: 
—29% to 32%) compared with women from the same birth cohort, living in 
Arnhem. In the relevant period, after a time lag of 10 years from the start of 
the programme, this reduction rose to 20% (95% confidence interval: —23% 
to 48%). Although a shift towards a reduction emerges, the data are unfortu-
nately as yet inconclusive. 
With the data of the Nijmegen project available, this thesis is a study of the 
determinants of the effect on breast cancer mortality. Because of the differen-
tial effect of age on the effect of screening, special emphasis is placed on 
age-specific differences regarding the disease process and factors related to the 
screening process. 
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Our assessment of early indicators of screening effectiveness is based on the 
proportion of screen-detected cancers among all cancers and on the disease 
stage at diagnosis. Only about one third of the cancers in women younger than 
50 years of age were screen-detected, compared with approximately one half 
in women 50-69 years old. A significantly lower frequency of advanced stages 
was observed in screen-detected versus clinically diagnosed cancers in women 
50 years of age or older but not in women under age 50. 
The study of the long-term prognosis of patients with early invasive breast 
cancer reveals that it is more difficult to improve survival in younger patients 
through early detection partly because of an apparent early metastatic potential 
of their tumours. Only if a substantial proportion of the invasive cancers are 
detected at a diameter as small as 1 cm might a reduction in breast cancer 
mortality in women younger than 50 years of age be expected. 
Moreover, to observe a beneficial effect of screening, if any, in women 
younger than age 50 years, more frequent screening than in the older age 
group is necessary because of the higher growth rate of tumours in younger 
patients. The median volume doubling time of cancers diagnosed in women 
younger than 50 years of age was approximately half that of cancers diagnosed 
in older women. The higher growth rate of the tumour in younger patients 
results in a relatively large number of interval cancers, i.e., cancers diagnosed 
in the interscreening interval following a negative examination. 
Another explanation of the relatively large number of interval cancers is that 
potentially detectable preclinical cancers present at screening had a higher 
probability to be missed by the mammographie screening test in younger 
women because of dense breast parenchyma. To estimate the number of can-
cers missed by the screening test, we limited the number of interval cancers 
by excluding those cases that are expected to have surfaced in the interval 
period because of a high growth rate. A poor performance of the mammogra-
phie screening test in the under age 50 group was inferred. 
Given the lack of information about the effect of screening on mortality, as 
well as the recent insight about tumour progress in younger women, it was 
concluded that further research is needed to determine whether breast cancer 
screening in women aged under 50 reduces breast cancer mortality and, if so, 
to what extent. To resolve the question of screening efficacy in women 40 to 
49 years, plans are being made to conduct a new international trial. To ensure 
adequate statistical power, a very large number of women have to be enrolled. 
For the discussion of the feasibility of such a trial we compared two 
approaches for sample size determination. Restricting attention to the breast 
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cancer deaths that occur among comparable groups of breast cancer patients 
has been shown to be a more efficient approach than an analysis in which all 
women entered into the trial are considered at risk of dying from breast cancer 
(population mortality analysis). It is illustrated that when comparability of 
cases can be reached, such a case mortality analysis requires 15-30% fewer 
women to be enrolled. 
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SAMENVATTING 
In het begin van de jaren negentig zijn verschillende internationale conferenties 
gehouden om het effect van mammografische screening naar borstkanker te 
evalueren. Over het nut van deze periodieke screening voor vrouwen ouder 
dan 50 jaar is men het in grote lijnen wel eens. De resultaten van de gerando-
miseerde onderzoeken laten zonder twijfel zien dat periodiek bevolkingsonder-
zoek naar borstkanker voor vrouwen ouder dan 50 jaar de sterfte aan borst-
kanker doet dalen. Mammografische screening in de leeftijdsgroep jonger dan 
50 jaar is echter controversieel. Deze zou wel eens minder effectief kunnen 
zijn. Mede gezien het relatief geringe aantal vrouwen jonger dan 50 jaar 
betrokken bij de diverse proefbevolkingsonderzoeken, kon geen definitieve 
conclusie worden getrokken. In dit proefschrift zijn de resultaten van het 
bevolkingsonderzoek in Nijmegen, het langst lopende project in de wereld, 
geanalyseerd om een bijdrage te kunnen leveren aan de discussie omtrent het 
nut van het screenen van jongere vrouwen. 
Het Nijmeegse tweejaarlijkse proefbevolkingsonderzoek voor de vroege 
opsporing van borstkanker is in 1975 van start gegaan. Vanaf de eerste scree-
ningsronde zijn alle vrouwen die op 1 januari 1975 tussen de 35 en 65 jaar 
oud waren (n=23.0OO), uitgenodigd om deel te nemen. In de volgende rondes 
zijn ook de oudere vrouwen (n=7.700) uitgenodigd. Vanaf de vijfde ronde 
worden ook de vrouwen die ondertussen de 40 jarige leeftijd hadden bereikt 
uitgenodigd om deel te nemen. 
De uiteindelijke evaluatie van het effect van mammografische screening 
geschiedt aan de hand van de sterfte aan borstkanker. De cumulatieve sterfte 
aan borstkanker onder Nijmeegse vrouwen die bij de start van het bevolkings-
onderzoek jonger dan 50 jaar waren, laat na een periode van 16 jaar een niet 
significante vermindering zien van 6% (95% betrouwbaarheidsinterval: —29% 
tot 32%) vergeleken met Arnhemse vrouwen uit hetzelfde geboortecohort. In 
de relevante studieperiode, d.w.z. vanaf 10 jaar na de start van het program-
ma, is de reductie 20% (95% betrouwbaarheidsinterval: —23% tot 48%). 
Hoewel er een verschuiving naar een vermindering in de sterfte aan borstkan-
ker optreedt, kan nog geen definitieve conclusie worden getrokken. 
De factoren die bepalend zijn voor het effect op de sterfte aan borstkanker 
zijn in dit proefschrift nader bestudeerd. Vanwege de modificerende invloed 
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van leeftijd op het effect van screening, is speciale nadruk gelegd op leeftijds-
specifieke verschillen met betrekking tot het ziekteproces en factoren die sa-
menhangen met het screeningsproces. 
De vroege evaluatie van het uiteindelijke effect van screening op de sterfte 
is gebaseerd op het percentage tumoren dat ontdekt is bij screening en op het 
ziektestadium bij diagnose. Slechts een derde van de tumoren bij vrouwen 
jonger dan 50 jaar is bij screening ontdekt, vergeleken met bijna de helft bij 
vrouwen 50-69 jaar oud. De overige tumoren zijn naar aanleiding van sympto-
men klinisch gediagnostiseerd tussen twee opeenvolgende screeningsronden in 
of bij vrouwen die niet hebben deelgenomen aan de screening. Een gunstiger 
ziektestadium, vergeleken met klinisch gediagnostiseerde tumoren, wordt 
alleen gezien voor de bij screening ontdekte tumoren van vrouwen ouder dan 
50 jaar, maar niet voor die van vrouwen jonger dan 50 jaar. 
Het onderzoek naar de lange termijn prognose (overlevingskansen) van pa-
tiënten met kleine invasieve tumoren laat zien dat het moeilijker is de overle-
ving van jongere patiënten te verbeteren door het vroeg vaststellen van de 
ziekte. Dit kan gedeeltelijk worden verklaard doordat bij jongere patiënten de 
invasieve tumoren sneller uitzaaien. Alleen als een aanzienlijk deel van de 
invasieve tumoren wordt gedetecteerd bij een diameter van hooguit 1 cm, dan 
mag een vermindering van de sterfte aan borstkanker bij vrouwen jonger dan 
50 jaar worden verwacht. 
Om een gunstig effect van screening te kunnen bewerkstelligen bij vrouwen 
jonger dan 50 jaar, is het bovendien noodzakelijk vaker te screenen dan in de 
oudere groep vanwege de snellere groei van tumoren bij jongere patiënten. De 
mediane verdubbelingstijd van het volume van tumoren gediagnostiseerd bij 
vrouwen jonger dan 50 jaar is ongeveer de helft van die van tumoren ge-
diagnostiseerd bij oudere vrouwen. De hogere groeisnelheid van tumoren bij 
jongere patiënten resulteert in een relatief groot aantal intervalcarcinomen, 
d.w.z. tumoren gediagnostiseerd tussen twee opeenvolgende screeningsonder-
zoeken. 
Een andere verklaring voor het relatief grote aantal intervalcarcinomen is 
dat preklinische carcinomen bij jongere vrouwen een grotere kans hebben 
gemist te worden bij de mammografische screeningstest vanwege de dichtere 
structuur van het borstparenchym. Het aantal tumoren dat gemist is bij de 
screeningstest kan geschat worden door het aantal intervalcarcinomen te ver-
minderen met het verwachte aandeel aan snel groeiende tumoren. Voor pa-
tiënten jonger dan 50 jaar blijkt dat bij screening ongeveer 60% van de poten-
tieel detecteerbare tumoren die klinisch manifest zouden worden binnen één 
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jaar na screening, ook worden ontdekt. Deze sensitiviteit is lager dan die 
verkregen voor patiënten ouder dan 50 jaar, die minstens 80% is. Voor tumo-
ren die klinisch manifest zouden worden 12-18 maanden na screening, daalt in 
de leeftijdsgroep jonger dan 50 jaar de sensitiviteit naar 20% en in de oudere 
leeftijdsgroep naar ongeveer 60%. Deze analyse laat zien dat de mammografi-
sche screeningstest voor vrouwen jonger dan 50 jaar een slechte sensitiviteit 
heeft. 
Het gebrek aan informatie over het effect van screening op de sterfte te 
zamen met de nieuwe inzichten over het tumorverloop bij jongere vrouwen, 
rechtvaardigt nader onderzoek om vast te stellen of bevolkingsonderzoek naar 
borstkanker voor vrouwen jonger dan 50 jaar de sterfte aan borstkanker ver-
mindert en met hoeveel. Om de vraag naar de effectiviteit van screening voor 
vrouwen van 40 tot 49 jaar op te lossen, worden thans plannen gemaakt voor 
een nieuwe internationale trial. Een zeer groot aantal vrouwen zal moeten 
deelnemen om verzekerd te zijn van een adequaat statistisch onderscheidings-
vermogen. Ten behoeve van de discussie omtrent de haalbaarheid van zo'n 
trial, zijn voor de bepaling van de steekproefomvang twee manieren van 
aanpak vergeleken. Het evalueren van de sterfte aan borstkanker in vergelijk-
bare groepen van patiënten met borstkanker ('case mortality analysis') is 
efficiënter dan een analyse waarin de sterfte aan borstkanker onder alle 
vrouwen die aan de trial meedoen wordt geëvalueerd ('population mortality 
analysis'). Aangezien de trial zal worden uitgevoerd in gebieden waar scree-
ning voor alle vrouwen vanaf 50 jaar reeds geïmplementeerd is, kan vergelijk-
baarheid verkregen worden door ook de patiënten gedetecteerd bij de scree-
ning op leeftijd 50 op te nemen in de patiëntgroepen. Geïllustreerd wordt dat 
bij een dergelijke case mortality analysis 15-30% minder vrouwen in de trial 
betrokken hoeven te worden. 
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1. I let landelijk bevolkingsonderzoek naar borstkanker op de wijze zoals dat nu 
elke 2 jaar plaatsvindt bij vrouwen tussen de 50 en 70 jaar, dient niet te 
worden uitgebreid naar jongere vrouwen (Dit proefschrift). 
2. Vanwege de snellere groei van borstkanker bij jongere patiënten dient een 
eventueel bevolkingsonderzoek naar borstkanker bij vrouwen jonger dan 
50 jaar jaarlijks plaats te vinden (Dit proefschrift). 
3. Ilei is moeilijker door vroege opsporing de prognose van jongere patiënten 
met borstkanker te verbeteren gedeeltelijk vanwege een frequentere uitzaaiing 
van kleine tumoren (Dit proefschrift). 
4. Vanwege het hoge percentage bij mammografische screening opgespoorde 
ductale in situ carcinomen met sterk uiteenlopende maligniteitsgraad, dient 
meer onderzoek te worden gedaan naar het natuurlijk verloop van deze 
mammacarcinomen. 
5. Hel is niet mogelijk om twee schone stukken metaal elkaar tot op willekeurig 
kleine afstand te laten naderen (J. van Ruitenbeek, ¡995). 
6. Het is een verwerpelijke werkwijze om de keuze voor een statistische 
techniek te laten afhangen van het toetsresultaat van de vooronderstellingen 
(./. Oosterhoff 1969). 
7. De uitdrukking 'In der Beschränkung zeigt sich der Meister' geldt ook voor 
de in een onderzoek uil te voeren data-analyses. 
8. Het toepassen van ingewikkelde statistische analyses is vaak eerder een vorm 
van onkunde dan van kennis. 
9. Het voorstel van de minister van Onderwijs, Cultuur en Wetenschap om de 
universiteiten te financieren op basis van het aantal getuigschriften in plaats 
van het aantal studenten, verlaagt het niveau van het onderwijs. 
10. Het bevorderen van de fiets als vervoer-, transport- en recrealiemiddcl dient 
nog steeds een grotere rol te spelen in de discussie over milieu-, parkeer- en 
filcproblemalick. 
11. Een milieuvriendelijke variant van carpoolen is samen op de tandem. 
12. Statistiek is net een sprookje: je kunt het steeds weer vertellen, het blijft 
nieuw. 


